Nano-delivery system and therapeutic and diagnostic use thereof

Abstract

To provide a generic platform for delivering molecules with low blood-brain barrier (BBB) penetration into the brain.SOLUTION: The nano-delivery system is based on a core nanoparticle that is conjugated through a first polymeric linker to a brain-internalizing transporter moiety, and is further conjugated to a second polymeric linker bound to an active agent selected from a biologically active molecule or a labeling molecule. A process for preparation of the nano-delivery system is further provided. The present invention further provides pharmaceutical compositions comprising the nano-delivery system and its use in therapeutic and / or diagnostic methods.SELECTED DRAWING: None

Description

[Technical Field]

[0001] The present invention is in the field of brain-targeted nanodelivery systems for therapeutic and diagnostic uses. [Background technology]

[0002] A significant problem in the treatment of neurodegenerative disorders and diseases is the difficulty of delivering important therapeutic and diagnostic agents to the brain across the blood-brain barrier (BBB). The BBB is a highly selective, semipermeable boundary that separates circulating blood from the central nervous system (CNS). The BBB primarily functions as a protective barrier for the brain, preventing the migration of various elements, including hormones, neurotransmitters, or neurotoxins, from the bloodstream into the CNS. Specific and selective transporters at the BBB supply the CNS with glucose, free fatty acids, amino acids, vitamins, minerals, and electrolytes, but nearly all high-molecular-weight drugs and over 98% of low-molecular-weight drugs cannot cross the BBB.

[0003] Various nanomaterial-based drug delivery systems have been developed to overcome the limitations associated with the BBB.

[0004] US Patent No. 10,182,986 is directed to a method of delivering nanoparticles across the blood-brain barrier to the brain of a subject by administering to the subject nanoparticles having a nanoparticle core and a targeting agent.

[0005] Ruan, Shaobo et al. (Biomaterials 37 (2015): 425-435) present a gold nanoparticle-based delivery system that carries doxorubicin (DOX) via an acid-responsive linker, hydrazone, and is functionalized with angiopep-2, a specific ligand for low-density lipoprotein receptor-related protein 1 (LRP1), which can mediate the system's penetration through the blood-brain barrier and targeting to glioma cells.

[0006] Shilo, Malka et al. (Nanoscale 6.4 (2014): 2146-2152) address the transport of insulin-targeted gold nanoparticles (INS-GNPs) through the blood-brain barrier for imaging and therapeutic applications.

[0007] There remains an unmet need for an efficient system for transporting therapeutic and / or diagnostic agents across the BBB and delivering them into the brain. There is a strong demand for a versatile platform that can deliver a wide variety of agents into the brain. Summary of the Invention

[0008] The present invention provides a versatile platform for delivering molecules with low blood-brain barrier (BBB) ​​permeability into the brain. The delivery system is based on a core nanoparticle that is conjugated to a brain-internalizing transporter moiety via a first polymer linker and further conjugated to a second polymer linker that can bind to a therapeutic or diagnostic agent of interest. Therefore, the delivery system of the present invention can be useful for the treatment and / or diagnosis of a wide range of brain-related diseases or disorders.

[0009] The present inventors have demonstrated that various types of molecules with poor BBB permeability, including antibodies, peptides, and small molecules, could be efficiently permeated into mouse brains while conjugated to the delivery system of the present invention, where the core nanoparticle was a gold nanoparticle (GNP) or iron oxide nanoparticle, and the brain-internalizing transporter moiety was insulin or transferrin. The present invention is based, in part, on the surprising discovery that the relative lengths of the first and second polymer linkers significantly affect the permeation of the delivery system through the BBB. Specifically, it was unexpectedly discovered that efficient BBB penetration of GNPs conjugated to insulin and antibodies was achieved when polymer linkers of different sizes were used to conjugate the insulin and antibody to the core nanoparticle. Even more surprisingly, it was found that the relative amounts of linkers used to conjugate the antibody affected the permeation efficiency of the delivery system into the brain.

[0010] One beneficial feature of the delivery systems of the present invention is that the activity of therapeutic agents conjugated to the delivery systems remains intact and, therefore, does not need to be separated from the nanoparticles after penetration of the BBB, for example, by using a cleavable linker. Specifically, it was unexpectedly found that antibodies attached to the nanodelivery systems of the present invention retained their activity and functionality despite being conjugated by a stable, non-cleavable covalent bond.

[0011] According to one aspect, a nanodelivery system is provided that includes an inorganic nanoparticle attached to a first linear polymer linker and a second linear polymer linker, wherein the first linear polymer linker and the second linear polymer linker have substantially different lengths; a brain-internalizing transporter moiety conjugated to the first linear polymer linker; and an active agent selected from a biologically active molecule or a labeling molecule, which is conjugated to the second linear polymer linker.

[0012] According to some embodiments, the first polymer linker and the second polymer linker are non-cleavable under physiological conditions.

[0013] According to some embodiments, the first linear polymer linker and the second linear polymer linker have a difference in their respective molecular weights of at least about 1400 Da. According to further embodiments, the molecular weights of the first linear polymer linker and the second linear polymer linker are in the range of 1,000 to 10,000 Da. In certain embodiments, the molecular weight of the first linear polymer linker is higher than the molecular weight of the second linear polymer linker.

[0014] According to some embodiments, the first linear polymer linker is composed of repeating monomer units and the second linear polymer linker is composed of the same repeating monomer units as the first linear polymer linker, and the first linear polymer linker has a different number of repeating monomer units than the second linear polymer linker.

[0015] According to some embodiments, the brain-internalizing transporter moiety is covalently conjugated to a first linear polymer linker via a first functional end group of the linker, and the active agent is covalently conjugated to a second linear polymer linker via a second functional end group of the linker. In further embodiments, the first functional end group and the second functional end group are the same.

[0016] According to certain embodiments, the inorganic nanoparticles are attached to the second linear polymer linker via a sulfide bond, and the active agent is conjugated to the second linear polymer linker via an amide bond.

[0017] According to some embodiments, the first linear polymer linker comprises about 5% mol to 60% mol of all polymer linkers attached to the inorganic nanoparticles.

[0018] According to some embodiments, the active agent is a biologically active molecule. The active agent may be selected from the group consisting of a polymer, a peptide, a small molecule, an oligonucleotide, an antisense RNA, and any combination thereof. In certain embodiments, the polymer is an antibody. In further embodiments, the first linear polymer linker comprises about 10% mol to 40% mol of the total polymer linkers attached to the inorganic nanoparticles.

[0019] According to some embodiments, the second linear polymer linker comprises about 5% mol to 60% mol of the total polymer linkers attached to the inorganic nanoparticles.

[0020] According to some embodiments, the first linear polymer linker and the second linear polymer linker independently comprise a polymer selected from the group consisting of polyethers, polyacrylates, polyanhydrides, polyvinyl alcohols, polysaccharides, poly(N-vinylpyrrolidone), polyglycerol (PG), poly(N-(2-hydroxypropyl)methacrylamide), polyoxazolines, poly(amino acid)-based hybrids, recombinant polypeptides, derivatives, and combinations thereof. According to certain embodiments, at least one of the first linear polymer linker and the second linear polymer linker is a polyether. In some exemplary embodiments, the polyether is polyethylene glycol (PEG). The polyethylene glycol may be selected from thiolated PEG acid (HS-PEG-COOH) and thiolated PEG amine (HS-PEG-NH2), wherein the thiolated end is attached to an inorganic nanoparticle and the acid or amine end is conjugated to a brain-internalizing transporter moiety or an active agent.

[0021] According to some embodiments, the nanodelivery system further comprises a third polymer linker attached to the inorganic nanoparticle, the third polymer linker being monofunctional. According to some embodiments, the third polymer linker comprises a polymer selected from the group consisting of polyethers, polyacrylates, polyanhydrides, polyvinyl alcohols, polysaccharides, poly(N-vinylpyrrolidone), polyglycerin (PG), poly(N-(2-hydroxypropyl)methacrylamide), polyoxazolines, poly(amino acid)-based hybrids, recombinant polypeptides, derivatives and combinations thereof. In some exemplary embodiments, the third polymer linker comprises a polyether, and the polyether is methoxypolyethylene glycol (mPEG).

[0022] According to some embodiments, the inorganic nanoparticles are selected from the group consisting of metal nanoparticles, metal oxide nanoparticles, ceramic nanoparticles, and any combination thereof. The metal may be selected from the group consisting of gold, silver, platinum, iron, and any combination thereof. The metal oxide may be selected from the group consisting of iron oxide, magnesium oxide, nickel oxide, cobalt oxide, aluminum oxide, zinc oxide, copper oxide, manganese oxide, and any combination thereof. In some exemplary embodiments, the inorganic nanoparticles are selected from the group consisting of gold, iron(III) oxide, and iron(II,III) oxide. According to some embodiments, the inorganic nanoparticles have a diameter of 10 to 160 nm.

[0023] According to some embodiments, the brain-internalizing transporter moiety is selected from the group consisting of insulin, an antibody specific for the insulin receptor, transferrin, an antibody specific for the transferrin receptor, a polypeptide that specifically binds to the transferrin receptor, a polypeptide that specifically binds to the insulin receptor, insulin-like growth factor 1, an antibody specific for insulin-like growth factor receptor 1, a polypeptide that specifically binds to insulin-like growth factor receptor 1, apolipoprotein A1, B, or E, lactoferrin, angiopep-2, low-density lipoprotein, an antibody specific for low-density lipoprotein receptor or lipoprotein receptor-related protein, a polypeptide that specifically binds to low-density lipoprotein receptor or lipoprotein receptor-related protein, an antibody specific for the diphtheria toxin receptor, a polypeptide that specifically binds to the diphtheria toxin receptor, a BBB-permeable cell-penetrating peptide (CPP), and any combination thereof. In certain embodiments, the brain-internalizing transporter moiety is insulin.

[0024] According to some exemplary embodiments, the inorganic nanoparticles are gold nanoparticles, the first linear polymer linker is a thiolated PEG5000 acid or a thiolated PEG5000 amine, the second linear polymer linker is a thiolated PEG3500 acid or a thiolated PEG3500 amine, and the brain-internalizing transporter moiety is insulin.

[0025] According to some exemplary embodiments, the inorganic nanoparticles are iron oxide nanoparticles, the first linear polymer linker is a thiolated PEG5000 acid or a thiolated PEG5000 amine, the second linear polymer linker is a thiolated PEG3500 acid or a thiolated PEG3500 amine, and the brain-internalizing transporter moiety is insulin.

[0026] According to some exemplary embodiments, the inorganic nanoparticles are gold nanoparticles, the first linear polymer linker is a thiolated PEG1000 acid or a thiolated PEG1000 amine, the second linear polymer linker is a thiolated PEG5000 acid or a thiolated PEG5000 amine, and the brain-internalizing transporter moiety is insulin.

[0027] According to some exemplary embodiments, the inorganic nanoparticles are gold nanoparticles, the first linear polymer linker is a thiolated PEG5000 acid or a thiolated PEG5000 amine, the second linear polymer linker is a thiolated PEG3500 acid or a thiolated PEG3500 amine, and the brain-internalizing transporter moiety is transferrin.

[0028] In another aspect, there is provided a process for preparing a nanodelivery system according to various embodiments described above, the process comprising, sequentially: (a) partially coating the surface of an inorganic nanoparticle with a first linear polymer linker, followed by conjugating said first linear polymer linker to a brain internalization transporter moiety; and (b) partially coating the surface of the inorganic nanoparticle with a second linear polymer linker, followed by conjugating said second linear polymer linker to an active agent, wherein steps (a) and (b) can be performed in any order.

[0029] According to some embodiments, the first polymer linker has a first functional end group configured to bind to a brain-internalizing transporter moiety and the second polymer linker has a second functional end group configured to bind to an active agent, and the first functional group and the second functional group are the same.

[0030] According to some embodiments, the process further comprises partially coating the surface of the inorganic nanoparticles with a third polymer linker, said polymer linker being a monofunctional linker.

[0031] According to some embodiments, the active agent is an antibody or a peptide, and step (a) is performed before step (b).

[0032] According to some embodiments, the active agent is a small molecule and step (a) is performed after step (b).

[0033] According to some embodiments, each of the first linear polymer linker and the second linear polymer linker is added in an amount suitable to cover 5% to 60% of the surface of the inorganic nanoparticle.

[0034] In yet another aspect, a pharmaceutical composition is provided that includes a nanodelivery system according to various embodiments set forth above and a pharmaceutically acceptable carrier.

[0035] According to some embodiments, the pharmaceutical composition is formulated for at least one of intravenous (IV), intranasal (IN), and intrathecal (IT) administration. According to some embodiments, the pharmaceutical composition is for use in preventing, treating, and / or monitoring a brain-related disease or disorder in a subject in need thereof.

[0036] In yet another aspect, there is provided a method for preventing, treating, and / or monitoring a brain-related disease or disorder in a subject in need thereof, the method comprising administering to the subject a pharmaceutical composition according to various embodiments described above.

[0037] According to some embodiments, the pharmaceutical composition is administered to the subject by at least one of intravenous (IV), intranasal (IN), and intrathecal (IT) administration.

[0038] According to some embodiments, the method further comprises imaging the brain of the subject, thereby assessing accumulation of the nanodelivery system in the brain of said subject. The imaging may be performed using an imaging system selected from the group consisting of computed tomography (CT), X-ray imaging, magnetic resonance imaging (MRI), positron emission tomography (PET), single photon emission computed tomography (SPECT), ultrasound (US), and any combination thereof.

[0039] In yet another aspect, a nanodelivery system is provided comprising an inorganic nanoparticle attached to a first linear polymer linker and a second linear polymer linker, wherein the first linear polymer linker and the second linear polymer linker have substantially different lengths, and a brain-internalizing transporter moiety conjugated to the first linear polymer linker, wherein the second polymer linker has a free functional end group configured for conjugating an active agent selected from a biologically active molecule or a labeling molecule.

[0040] According to some embodiments, the first polymer linker and the second polymer linker are non-cleavable under physiological conditions.

[0041] According to some embodiments, the first linear polymer linker and the second linear polymer linker have a difference in their respective molecular weights of at least about 1,000 Da. According to some embodiments, the first linear polymer linker and the second linear polymer linker have a difference in their respective molecular weights of at least about 1,400 Da. According to further embodiments, the molecular weights of the first linear polymer linker and the second linear polymer linker are in the range of 1,000 to 10,000 Da. In certain embodiments, the molecular weight of the first linear polymer linker is higher than the molecular weight of the second linear polymer linker.

[0042] According to some embodiments, the first linear polymer linker is composed of repeating monomer units and the second linear polymer linker is composed of the same repeating monomer units as the first linear polymer linker, and the first linear polymer linker has a different number of repeating monomer units than the second linear polymer linker.

[0043] According to some embodiments, the brain-internalizing transporter moiety is covalently conjugated to a first linear polymer linker via a first functional end group of said linker. According to some embodiments, the first functional end group of the first linear polymer linker and the functional end group of the second linear polymer linker configured for conjugating an active agent are the same.

[0044] According to some embodiments, the first linear polymer linker comprises about 5% to 60% mol of the total polymer linkers attached to the inorganic nanoparticles. In further embodiments, the first linear polymer linker comprises about 10% to 40% mol of the total polymer linkers attached to the inorganic nanoparticles. According to some embodiments, the second linear polymer linker comprises about 5% to 60% mol of the total polymer linkers attached to the inorganic nanoparticles.

[0045] According to some embodiments, the first linear polymer linker and the second linear polymer linker independently comprise a polymer selected from the group consisting of polyethers, polyacrylates, polyanhydrides, polyvinyl alcohols, polysaccharides, poly(N-vinylpyrrolidone), polyglycerol (PG), poly(N-(2-hydroxypropyl)methacrylamide), polyoxazolines, poly(amino acid)-based hybrids, recombinant polypeptides, derivatives, and combinations thereof. According to certain embodiments, at least one of the first linear polymer linker and the second linear polymer linker is a polyether. In certain embodiments, the polyether is polyethylene glycol (PEG). The polyethylene glycol may be selected from thiolated PEG acid (HS-PEG-COOH) and thiolated PEG amine (HS-PEG-NH2), wherein the thiolated end is attached to an inorganic nanoparticle and the acid or amine end is configured to be conjugated to a brain internalization transporter moiety or an active agent.

[0046] According to some embodiments, the nanodelivery system further comprises a third polymer linker attached to the inorganic nanoparticle, the third polymer linker being monofunctional. According to some embodiments, the third polymer linker comprises a polymer selected from the group consisting of polyethers, polyacrylates, polyanhydrides, polyvinyl alcohols, polysaccharides, poly(N-vinylpyrrolidone), polyglycerin (PG), poly(N-(2-hydroxypropyl)methacrylamide), polyoxazolines, poly(amino acid)-based hybrids, recombinant polypeptides, derivatives and combinations thereof. In some exemplary embodiments, the third polymer linker comprises a polyether, and the polyether is methoxypolyethylene glycol (mPEG).

[0047] According to some embodiments, the inorganic nanoparticles are selected from the group consisting of metal nanoparticles, metal oxide nanoparticles, ceramic nanoparticles, and any combination thereof. The metal may be selected from the group consisting of gold, silver, platinum, iron, and any combination thereof. The metal oxide may be selected from the group consisting of iron oxide, magnesium oxide, nickel oxide, cobalt oxide, aluminum oxide, zinc oxide, copper oxide, manganese oxide, and any combination thereof. In some embodiments, the inorganic nanoparticles are selected from the group consisting of gold, iron(III) oxide, and iron(II,III) oxide. According to some embodiments, the inorganic nanoparticles have a diameter of 10 to 160 nm.

[0048] According to some embodiments, the brain-internalizing transporter moiety is selected from the group consisting of insulin, an antibody specific for the insulin receptor, transferrin, an antibody specific for the transferrin receptor, a polypeptide that specifically binds to the transferrin receptor, a polypeptide that specifically binds to the insulin receptor, insulin-like growth factor 1, an antibody specific for insulin-like growth factor receptor 1, a polypeptide that specifically binds to insulin-like growth factor receptor 1, apolipoprotein A1, B, or E, lactoferrin, angiopep-2, low-density lipoprotein, an antibody specific for low-density lipoprotein receptor or lipoprotein receptor-related protein, a polypeptide that specifically binds to low-density lipoprotein receptor or lipoprotein receptor-related protein, an antibody specific for the diphtheria toxin receptor, a polypeptide that specifically binds to the diphtheria toxin receptor, a BBB-permeable cell-penetrating peptide (CPP), and any combination thereof. In certain embodiments, the brain-internalizing transporter moiety is insulin.

[0049] Further embodiments and the full scope of applicability of the present invention will become apparent from the detailed description given hereinafter. It should be understood, however, that the detailed description and specific examples, while indicating preferred embodiments of the invention, are given by way of example only, since various changes and modifications within the spirit and scope of the invention will become apparent to those skilled in the art from this detailed description. [Brief explanation of the drawings]

[0050] [Figure 1] Schematic of i) a first linear polymer linker (2) conjugated to insulin (3), ii) a second, shorter linear polymer linker (4) conjugated to a bioactive molecule (e.g., an antibody; 5), and iii) a gold nanoparticle (GNP; 1) attached to a polymer moiety with an inert end group (6). [Figure 2] UV-visible spectroscopy of EGFR&Ins-GNPs after various synthesis steps: before coating (GNP); after coating with PEG (~5 kDa) and insulin (GNP+PEG+Ins); after coating with an additional PEG linker (~3.5 kDa; GNP+PEG+Ins+PEG; and after final EGFR Ab conjugation (GNP+PEG+Ins+PEG+Ab). [Figure 3] SDS-PAGE of free insulin (free INS), free EGFR Ab (free Ab), GNPs, PEG-coated GNPs (GNPs+PEG), insulin-coated GNPs (GNPs+PEG+INS), and EGFR+Ins-GNPs (GNPs+PEG+INS+Ab). [Figure 4] Figure 4A-C. Representative microCT 3D volume-rendered images of a mouse brain 5 hours after the following treatments: intravenous (IV) administration of 200 μl of mPEG-GNPs (control; Figure 4A); intravenous (IV) administration of 200 μl of EGFR-Ins-GNPs (Figure 4B); and intranasal (IN) administration of 20 μl of EGFR-Ins-GNPs (Figure 4C). [Figure 5A] Quantification of the amount of Au (mg) found in mouse brain tissue at various time points after intravenous administration of EGFR&Ins-GNPs, as determined by ICP-MS analysis. [Figure 5B] Quantification of the amount of Au (mg) found in the kidney and liver of mice at various time points after intravenous administration of EGFR&Ins-GNPs, as determined by ICP-MS analysis. [Figure 6A]Quantification of the amount of Au found in mouse brain tissue 8 hours after intravenous administration of IgG1&Ins-GNP or free fluorescent IgG1 antibody, as measured by ICP-MS analysis (mg Au per gram of tissue). [Figure 6B] Representative confocal immunohistochemical staining fluorescence images of brain sections from mice treated with IgG1&Ins-GNP (right panel) or free fluorescent antibody (left panel). [Figure 7] Figures 7A-B. Representative super-resolution microscopy images of frontal sections of mouse brains treated with anti-Iba1&Ins-GNPs (Figure 7A) or free fluorescent anti-Iba1 (Figure 7B). [Figure 8] UV-visible spectroscopy of GNPs before coating (bare GNPs), GNPs after coating with PEG, and the final PEP&Ins-GNPs. [Figure 9] Figures 9A-B. Representative micro-CT images of mouse brains 6 hours after intravenous (IV) administration of PEP&Ins-GNPs. Figure 9A: WT mouse; Figure 9B: 5XFAD mouse. [Figure 9C] Quantification of the amount of Au found in brain tissue of WT mice (control) and 5XFAD mice (Alzheimer's disease) 6 h after intravenous administration of PEP&Ins-GNPs, as measured by ICP-MS analysis (mg of Au per gram of tissue). [Figure 9D] Fluorescence microscopy images (magnification ×20; scale bar = 100 μm) of coronal sections of the hippocampus from a control mouse (WT; top image) or a 5xFAD mouse (an Alzheimer's disease model mouse; bottom image) after 20 hours of incubation with fluorescently labeled PEP&Ins-GNPs. Images from left to right: cell nucleus localization (DAPI staining), Aβ plaque localization (6E10 staining), PEP&Ins-GNP localization, and the merged fluorescence image. [Figure 10A] Quantification of the amount of Au found in mouse brain tissue 8 h after intravenous administration of cisplatin + insulin-GNPs or free cisplatin, as determined by ICP-MS analysis (mg of Au per gram of tissue). [Figure 10B]Quantification of the amount of Pt found in mouse brain tissue 8 h after intravenous administration of cisplatin + insulin-GNPs or free cisplatin, as measured by ICP-MS analysis (mg of Pt per gram of tissue). [Figure 11] Reduction in transendothelial electrical resistance (TEER) of BMEC-like cells (iBMECs) after 2 hours of incubation with mPEG-GNPs (control particles), IgG1&Trf-GNPs, or IgG1&Ins-GNPs. [Figure 12A] Quantification of the amount of Au (mg per gram of tissue) found in the brain of mice 8 hours after intravenous administration of IgG1&Ins-GNPs with different insulin levels ranging from 5% to 50%. [Figure 12B] Quantification of the amount of Au (mg per gram of tissue) found in the brain of mice 8 h after intravenous administration of IgG1&Ins-GNPs with different IgG1 Ab levels ranging from 20% to 85%. [Figure 12C] Quantification of the amount of Au (mg per gram of tissue) found in the mouse brain 8 hours after intravenous administration of IgG1&Ins-GNPs prepared with different sized PEG linkers. DETAILED DESCRIPTION OF THE INVENTION

[0051] The present invention provides a universal nanodelivery system for delivering various types of molecules with low BBB permeability into the brain, as well as a process for preparing the system. The delivery system is based on a core nanoparticle conjugated to a brain-internalizing transporter moiety via a first polymer linker, which is further conjugated to a second polymer linker capable of binding a therapeutic or diagnostic agent. Without wishing to be bound by any theory or mechanism, it is hypothesized that the brain-internalizing transporter moiety facilitates the permeation of the entire conjugated system through the BBB into the brain. Therefore, the delivery system of the present invention may be useful for the treatment and / or diagnosis of a wide range of brain-related diseases or disorders. The present invention further provides pharmaceutical compositions and methods for therapeutic and / or diagnostic use.

[0052] The present invention is based, in part, on the surprising discovery that nanoparticles conjugated to a brain-internalizing transporter moiety (e.g., insulin) and a bioactive molecule can overcome the restrictive mechanisms of the blood-brain barrier and provide a nanodelivery system for targeted delivery of diagnostic and / or therapeutic agents into the brain without the need for release of the agent from the delivery system upon crossing the BBB. In diagnostics, this approach, in some embodiments, allows for early detection of neurodegenerative diseases. In therapeutics, in some embodiments, this approach allows for delivery of targeted therapeutic agents.

[0053] Nano Delivery System According to one aspect, (a) a nanoparticle attached to a first polymer linker and a second polymer linker, wherein the first and second polymer linkers have substantially different lengths; (b) a brain-internalizing transporter moiety conjugated to a first polymer linker, and (c) an active agent selected from a biologically active molecule or a labeling molecule, which is conjugated to a second polymer linker; A nanodelivery system is provided comprising:

[0054] According to another aspect, there is provided a nanodelivery system comprising a nanoparticle attached to a first polymer linker and a second polymer linker, and a brain internalization transporter moiety conjugated to the first polymer linker, wherein the first and second polymer linkers have substantially different lengths, and the second polymer linker has a free functional end group configured for conjugating an active agent selected from a biologically active molecule or a labeling molecule.

[0055] As used herein, the term "nanodelivery system" may be used interchangeably with the terms "particle" or "core-shell particle" and refers to a nanoparticle-based system capable of delivering an active agent selected from a bioactive substance or a labeling molecule, e.g., an imaging agent, to a target region, i.e., the brain of a subject, or in some embodiments, to a specific region within the brain of a control. In accordance with the principles of the present invention, the active agent is conjugated to the exterior surface of the core nanoparticle via a polymer linker, rather than being carried or encapsulated within the nanoparticle core.

[0056] In some embodiments, the present invention provides particles comprising a core and a shell, wherein the core comprises nanoparticles, and the shell comprises a bioactive or labeled molecule bound to a polymer, and a brain-internalizing transporter moiety bound to the polymer. As used herein, the term "shell" refers to the outer portion of the particle, which has a different composition from the core. In some embodiments, the volume / volume (v / v) ratio of the brain-internalizing transporter moiety in the shell is 5-60%.

[0057] The terms "nanoparticle" and "core nanoparticle," used interchangeably herein, refer to a particle having a diameter of 1 to 1000 nm that constitutes the center of the delivery system. The core nanoparticle is coated with a polymer layer comprising at least two polymers: a first polymer linker attached to a brain internalization transporter moiety and a second polymer linker having a free functional end group capable of binding to a bioactive or labeling molecule. In some embodiments, the second polymer is attached to a bioactive or labeling molecule. Thus, the delivery system of the present invention can be considered a core-shell particle, in which the core is a nanoparticle and the shell comprises a polymer linker containing each conjugated molecule.

[0058] In some embodiments, the nanoparticles are selected from the group consisting of metal nanoparticles, metal oxide nanoparticles, metal carbide nanoparticles, lipid nanoparticles, carbon-based nanoparticles, ceramic nanoparticles, polymeric nanoparticles, and liposomes. Each possibility represents a separate embodiment of the present invention. In some embodiments, the nanoparticles are inorganic nanoparticles. In some embodiments, the inorganic nanoparticles are selected from the group consisting of metal nanoparticles, metal oxide nanoparticles, and ceramic nanoparticles. In some embodiments, the inorganic nanoparticles are selected from the group consisting of metal nanoparticles and metal oxide nanoparticles. In some embodiments, the inorganic nanoparticles are metal nanoparticles. In other embodiments, the inorganic nanoparticles are metal oxide nanoparticles. In certain embodiments, the inorganic nanoparticles are selected from gold nanoparticles and iron oxide nanoparticles.

[0059] In some embodiments, the metal nanoparticles are magnetic nanoparticles. In some embodiments, the inorganic nanoparticles are magnetic nanoparticles. In some embodiments, the magnetic nanoparticles are contrast agents for magnetic resonance imaging (MRI). Any magnetic nanoparticles suitable for use as an MRI contrast agent may be used in the compositions and methods of the present invention. The magnetic particles may be at least partially formed from any material that is affected by a magnetic field. Examples of suitable materials include, but are not limited to, magnetite, hematite, ferrite, and materials containing one or more of iron, cobalt, manganese, nickel, chromium, gadolinium, neodymium, dysprosium, samarium, erbium, iron carbide, iron, or combinations thereof.

[0060] In some embodiments, the inorganic nanoparticles are contrast agents for computed tomography (CT) or X-ray imaging. In some embodiments, the inorganic nanoparticles are metal nanoparticles that can be used as contrast agents for CT or X-ray imaging. As will be apparent to those skilled in the art, any metal and / or combination of metals suitable for use in CT or X-ray imaging may be used in the metal nanoparticles of the present invention in embodiments related to diagnostic uses. In some embodiments, the metals that can be used to form the nanoparticles of the present invention are heavy metals or metals with high Z numbers. Examples of suitable metals include, but are not limited to, gold, silver, platinum, palladium, cobalt, iron, copper, tin, tantalum, vanadium, molybdenum, tungsten, osmium, iridium, rhenium, hafnium, thallium, lead, bismuth, gadolinium, dysprosium, holmium, and uranium, or combinations thereof.

[0061] According to some embodiments, the inorganic nanoparticles are metal nanoparticles selected from the group consisting of gold nanoparticles, silver nanoparticles, platinum nanoparticles, iron nanoparticles, copper nanoparticles, and mixtures or combinations thereof. Each possibility represents a separate embodiment. In some embodiments, the metal nanoparticles are gold (Au) nanoparticles.

[0062] In some embodiments, the inorganic nanoparticles are metal oxide nanoparticles. In some embodiments, the metal oxide nanoparticles are selected from the group consisting of iron oxide (Fe2O3 or Fe3O4), magnesium oxide, nickel oxide, cobalt oxide, aluminum oxide, zinc oxide, copper oxide, and manganese oxide, or any combination thereof. Each possibility represents a separate embodiment of the present invention. In some embodiments, the metal oxide nanoparticles comprise an iron oxide selected from iron(III) oxide and iron(II,III) oxide. In some embodiments, the metal oxide nanoparticles are iron oxide nanoparticles, and the iron oxide is selected from iron(III) oxide and iron(II,III) oxide.

[0063] In some embodiments, the nanoparticles are selected from the group consisting of lipid nanoparticles, carbon-based nanoparticles, ceramic nanoparticles, polymeric nanoparticles, and liposomes.

[0064] In some embodiments, the present invention provides a plurality of particles.

[0065] According to some embodiments, the particles, i.e., delivery systems, may be sized to a diameter of 5-500 nm, 6-400 nm, 8-300 nm, 10-300 nm, 10-200 nm, 10-180 nm, 10-160 nm, 10-150 nm, 10-100 nm, 20-90 nm, 20-80 nm, 20-70 nm, 20-60 nm, 25-100 nm, 25-90 nm, 25-80 nm, 25-70 nm, 25-60 nm, 25-50 nm, having a diameter of 30 to 60 nm, 40 to 200 nm, 40 to 150 nm, 40 to 120 nm, 40 to 100 nm, 40 to 80 nm, 40 to 60 nm, 50 to 300 nm, 50 to 250 nm, 50 to 200 nm, 50 to 180 nm, 50 to 150 nm, 60 to 200 nm, 70 to 180 nm, 80 to 180 nm, 90 to 170 nm, 100 to 160 nm, 100 to 200 nm, 150 to 200 nm, or 150 to 180 nm. According to some embodiments, the particles, i.e., delivery systems, have a diameter of 2 to 200 nm, 1 to 100 nm, 1 to 150 nm, 1 to 200 nm, 2 to 50 nm, 2 to 100 nm, 2 to 150 nm, 4 to 50 nm, 4 to 100 nm, 4 to 150 nm, or 4 to 200 nm. Each possibility represents a separate embodiment. According to some embodiments, the particles have a diameter of at least 1 nm, at least 2 nm, at least 5 nm, at least 10 nm, at least 15 nm, at least 20 nm, at least 25 nm, at least 30 nm, at least 35 nm, at least 40 nm, at least 45 nm, at least 50 nm, at least 55 nm, at least 60 nm, at least 70 nm, at least 80 nm, at least 90 nm, at least 100 nm, at least 110 nm, at least 120 nm, at least 130 nm, at least 140 nm, at least 150 nm, at least 160 nm, at least 180 nm, or at least 200 nm. Each possibility represents a separate embodiment.According to some embodiments, the particles have a diameter of at most 5 nm, at most 20 nm, at most 30 nm, at most 40 nm, at most 50 nm, at most 60 nm, at most 70 nm, at most 80 nm, at most 90 nm, at most 100 nm, at most 110 nm, at most 120 nm, at most 130 nm, at most 140 nm, at most 150 nm, at most 180 nm, at most 200 nm, at most 250 nm, at most 300 nm, at most 350 nm, at most 400 nm, at most 450 nm, or at most 500 nm. Each possibility represents a separate embodiment.

[0066] According to some implementations, the core nanoparticles may be 1-200 nm, 1-180 nm, 1-160 nm, 1-140 nm, 1-120 nm, 1-100 nm, 1-90 nm, 1-80 nm, 1-70 nm, 1-60 nm, 1-50 nm, 1-40 nm, 2-100 nm, 2-60 nm, 2-50 nm, 2-40 nm, 2-3 nm, 2-20 nm, 2-10 nm, 3-100 nm, 3-60 nm, 3-50 nm, 3-40 nm, 3-30 nm, 3-20 nm, 4-100 nm, 4-60 nm, 4-50 nm, 4-40 nm, 5-200 nm, 6-190 nm, 7-180 nm, 8-170 nm, 10-160 nm, 20-220 nm, 220 nm, 230 nm, 240 nm, 250 nm, 260 nm, 270 nm, 280 nm, 290 nm, 300 nm, 310 nm, 320 nm, 330 nm, 340 nm, 350 nm, 360 nm, 370 nm, 380 nm, 390 nm, 410 nm, 420 nm, 430 nm, 440 nm, 450 nm, 460 nm, 470 nm, 480 nm, 490 nm, 500 nm, 510 nm, 520 nm, 530 nm, 540 nm, 550 nm, 560 nm, 570 nm, 580 nm, 590 nm, 600 nm, 610 nm, 6 ~160nm, 10~150nm, 10~140nm, 10~120nm, 10~110nm, 10~100nm, 10~90nm, 10~80nm, 12~70nm, 14~60nm, 15~50nm, 15~40nm, 15~30nm, 20~30nm, 15~30nm, 20~90nm, 20~80 nm, 20~70nm, 20~60m, 20~50nm, 20~40nm, 20~30nm, 30~70nm, 30~60nm, 40~60nm, 10 ~200nm, 20~200nm, 30~200nm, 40~200nm, 50~200nm, 60~200nm, 70~200nm, 80~200nm and having a diameter of 90 to 200 nm, 100 to 200 nm, 110 to 190 nm, 120 to 170 nm, 130 to 160 nm, 100 to 160 nm, 80 to 160 nm, 60 to 160 nm, 40 to 160 nm, 20 to 160 nm, 10 to 160 nm, 20 to 150 nm, or 30 to 150 nm. Each possibility represents a separate embodiment. According to some implementations, the nanoparticles have a diameter of at least 1 nm, at least 2 nm, at least 3 nm, at least 4 nm, at least 5 nm, at least 10 nm, at least 12 nm, at least 15 nm, at least 18 nm, at least 20 nm, at least 25 nm, at least 30 nm, at least 35 nm, at least 40 nm, at least 45 nm, at least 50 nm, at least 60 nm, at least 70 nm, at least 80 nm, at least 90 nm, at least 100 nm, at least 110 nm, at least 120 nm, at least 130 nm, at least 140 nm, or at least 150 nm.Each possibility represents a separate embodiment. According to some implementations, the nanoparticles have a diameter of at most 5 nm, at most 10 nm, at most 15 nm, at most 20 nm, at most 30 nm, at most 40 nm, at most 50 nm, at most 60 nm, at most 70 nm, at most 80 nm, at most 90 nm, at most 100 nm, at most 120 nm, at most 140 nm, at most 160 nm, at most 180 nm, or at most 200 nm. Each possibility represents a separate embodiment.

[0067] The term "diameter" of a particle / nanoparticle as used herein may be used interchangeably with the term "size" of the particle / nanoparticle and refers to the maximum linear distance between two points on the surface of the described particle / nanoparticle. The term "diameter" as used herein encompasses the size of spherical and non-spherical particles and may refer to the actual size of the particle or its hydrodynamic diameter, including contributions from the solvation sphere. Any method known in the art can be used to determine particle size, such as transmission electron microscopy (TEM), scanning electron microscopy (SEM), and dynamic light scattering (DLS). The term "diameter" may refer to the average diameter of multiple particles measured by any of the above techniques.

[0068] In some embodiments, the core nanoparticle is coated with a polymer layer comprising at least two polymer moieties attached to said core nanoparticle, in some embodiments, the at least two polymer moieties are polymer linkers.

[0069] The term "coated" as used herein is intended to mean that a layer, e.g., a polymer layer comprising multiple polymer moieties, is chemically bonded to the surface of a core nanoparticle, thereby at least partially covering said core nanoparticle. A "nanoparticle coated with a polymer layer" means that each polymer moiety in the polymer layer is chemically bonded to the nanoparticle via a functional end group, e.g., a thiol group, of said polymer moiety. The chemical bond can be covalent, semi-covalent, or non-covalent.

[0070] The term "polymer segment" may be used interchangeably with the term "polymer" and refers to a molecule containing two or more repeating subunits linked in a linear, branched, hyperbranched, dendritic, or cyclic arrangement, or any combination thereof. In some embodiments, the term "polymer segment" refers to a molecule containing at least three repeating subunits linked in a linear, branched, hyperbranched, dendritic, or cyclic arrangement, or any combination thereof. Examples of subunits include alkylenes, arylenes, heteroalkylenes, amino acids, nucleic acids, saccharides, etc. Examples of polymer segments include, but are not limited to, poly(ethylene glycol) groups, poly(ethyleneamine) groups, and poly(amino acid) groups. The terms "polymer segment" and "polymer" also encompass polymer linkers. As used herein, the term "polymer linker" refers to a polymer segment that originally contains at least one functional / reactive group that allows for attachment to a substance, such as a nanoparticle. In some embodiments, the polymer linker is a bifunctional polymer having at least two functional / reactive groups that allow for attachment to at least two substances, thereby providing a link between the at least two substances. In some embodiments, the polymer linker is a monofunctional polymer, having one functional / reactive group that allows for attachment to one substance, e.g., a nanoparticle. It should be understood that the terms "monofunctional," "bifunctional," "functional group," etc., as used herein, refer to the polymer linker in its original form prior to attachment to the core nanoparticle and / or brain-internalizing transporter moiety or active agent.

[0071] In some embodiments, at least one of the first and second polymer linkers is a linear polymer linker. In some embodiments, the first polymer linker is a linear polymer linker. In some embodiments, the second polymer linker is a linear polymer linker. In some embodiments, the linear polymer linker is a bifunctional linear polymer having two functional / reactive groups at both ends of said linear polymer. In some embodiments, both the first and second polymer linkers are linear polymer linkers. In some embodiments, both the first and second polymer linkers are linear bifunctional polymer linkers having two functional / reactive groups at both ends of said linear polymer.

[0072] As used herein, the term "linear" polymer / polymer linker, in some embodiments, refers to a polymer / polymer linker in which at least 80% of the monomer units are connected linearly, i.e., in the form of a single polymer chain. In further embodiments, the term "linear" polymer / polymer linker refers to a polymer / polymer linker in which at least 90% of the monomer units are connected linearly. In yet further embodiments, the term "linear" polymer / polymer linker refers to a polymer / polymer linker in which about 100% of the monomer units are connected linearly. As used herein, the term "single polymer chain" refers to a polymer chain comprising monomers connected in such a way that the monomer units are linked to each other through two atoms, one in each monomer unit.

[0073] In some embodiments, the core nanoparticle is conjugated to a first polymer. In some embodiments, the core nanoparticle is conjugated to a second polymer. In some embodiments, the core nanoparticle is conjugated to a first and a second polymer. In some embodiments, the core nanoparticle is conjugated to a first, second, and a third polymer. In some embodiments, the core nanoparticle is conjugated to a first polymer linker. In some embodiments, the core nanoparticle is conjugated to a second polymer linker. In some embodiments, the core nanoparticle is conjugated to a first and a second polymer linker. In some embodiments, the core nanoparticle is conjugated to a first linear polymer linker. In some embodiments, the core nanoparticle is conjugated to a second linear polymer linker. In some embodiments, the core nanoparticle is conjugated to a first and a second linear polymer linker. In some embodiments, the core nanoparticle is conjugated to a first and a second polymer linker and an additional polymer moiety, wherein the additional polymer moiety is monofunctional, i.e., originally has a single functional end group configured for conjugating the aforementioned polymer to the core nanoparticle. In some embodiments, the additional polymer is a monofunctional linker.

[0074] The term "bound" may be used interchangeably with the term "conjugated." In some embodiments, the attachment is a covalent conjugation. The terms "covalent attachment," "covalently attached," "covalently linked," and "covalently bonded" are used interchangeably herein and refer to the formation of a chemical bond characterized by the sharing of electron pairs between atoms. For example, a covalently bound drug coating refers to a drug coating that forms a chemical bond with the functionalized surface of a substrate, as compared to binding to the surface by other means, such as adhesion or electrostatic interactions. It will be understood that drugs (e.g., polymers) covalently bound to a surface may also be attached via means in addition to covalent bonds.

[0075] In some embodiments, the polymer moiety and / or linker are attached to the outer surface of the core nanoparticle via a chemical bond selected from the group consisting of a covalent bond, a semi-covalent bond, and a non-covalent bond. Each possibility represents a separate embodiment of the present invention. In some embodiments, the polymer moiety and / or linker are attached to the outer surface of the core nanoparticle via a semi-covalent bond. As used herein, the term "semi-covalent bond" refers to a coordinate bond in which the shared electron pair forming the bond originates from the same atom. In the present disclosure, the semi-covalent bond may occur between a metal nanoparticle, such as a gold nanoparticle, and a thiol group.

[0076] In some embodiments, the first polymer linker comprises a polymer selected from the group consisting of polyethers, polyacrylates, polyanhydrides, polyvinyl alcohols, polysaccharides, poly(N-vinylpyrrolidone), polyglycerin (PG), poly(N-(2-hydroxypropyl)methacrylamide), polyoxazolines, poly(amino acid)-based hybrids, recombinant polypeptides, derivatives, and combinations thereof. Each possibility represents a separate embodiment of the present invention.

[0077] As used herein, the term "derivative" refers to a compound whose core structure is the same as or closely resembles that of the parent compound, but which has chemical or physical modifications, such as different or additional groups, including, but not limited to, alkoxy groups, carboxy groups, amine groups, methoxy groups, and thiol groups.

[0078] In some embodiments, the first polymer linker comprises a polyether. In some embodiments, the first polymer linker is a polyether. In some embodiments, the polyether is polyethylene glycol (PEG) or a derivative thereof.

[0079] Where appropriate, the abbreviation (PEG) is used in combination with a numerical suffix indicating the average molecular weight of the PEG. The form of PEG or PEG species is a PEG or PEG derivative having the specified average molecular weight.

[0080] As used herein, "PEG or a derivative thereof" refers to any compound containing at least one polyethylene glycol moiety. PEG exists in linear and branched forms, including multi-armed and / or grafted polyethylene glycols. As used herein, the term "PEG derivative" refers to PEG that has been modified by alkylation of the terminal hydroxyl group. In some embodiments, the terminal hydroxyl group is alkylated with a linear or branched C1-C6 alkyl. PEG may further comprise a functional group. PEG may be a monofunctional, bifunctional, or multifunctional polyethylene glycol.

[0081] Exemplary functional groups include, but are not limited to, the following: hydroxyl, carboxyl, thiol, amine, phosphate, phosphonate, sulfate, sulfite, sulfonate, sulfoxide, sulfone, amide, ester, ketone, aldehyde, cyano, alkyne, azide, and alkene, or combinations thereof.

[0082] In some embodiments, the brain internalizing transporter moiety is covalently conjugated to a first polymer linker via a first functional end group of the linker, and the active agent is covalently conjugated to a second polymer linker via a second functional end group of the linker. In some embodiments, the first functional end group and the second functional end group are the same. In other embodiments, the first functional end group and the second functional end group are different.

[0083] In some embodiments, the first polymer linker comprises a thiol (-SH) terminal group. In some embodiments, the first polymer linker is chemically bonded to the nanoparticle via the thiol (-SH) terminal group. In some embodiments, the first polymer linker is conjugated to the brain-internalizing moiety via an amide bond. In some embodiments, the nanoparticle is bonded to the first polymer linker via a sulfide bond, and the brain-internalizing transporter moiety is conjugated to the first polymer linker via an amide bond. In some embodiments, the first polymer linker in the nanodelivery system has the structure -SR-CONH-, where R is a polymer chain composed of repeating monomer units. In other embodiments, the first polymer linker in the nanodelivery system has the structure -SR-NHCO-, where R is a polymer chain composed of repeating monomer units. In some embodiments, the first polymer linker is selected from thiolated PEG acid (HS-PEG-COOH) and thiolated PEG amine (HS-PEG-NH2). It should be understood that the HS and COOH / NH2 terminal groups refer to the polymer linker prior to conjugation with the nanoparticle and brain-internalizing transporter moiety. In some embodiments, the thiol group is chemically bonded to the core nanoparticle, and the acid or amine group is covalently conjugated to the brain-internalizing transporter moiety. In some embodiments, the first polymer linker in the nanodelivery system has a structure selected from -S-PEG-C(O)- and -S-PEG-NH-.

[0084] In some embodiments, the first polymer linker is a non-cleavable linker. In some embodiments, the first polymer linker is non-cleavable under physiological conditions.

[0085] The term "non-cleavable" as used herein refers to a stable bond that is not sensitive to acids or bases, to reducing or oxidizing agents, or to enzymes found in cells or the circulatory system. In some embodiments, the first and / or second polymer linker lacks a pH-sensitive hydrazone. In some embodiments, the first and / or second polymer linker lacks a disulfide bond. In some embodiments, the first and / or second polymer linker lacks an ester bond. It should be understood that the term "the polymer linker is non-cleavable" is intended to encompass the bond between the nanoparticle and the polymer linker, the bond between each polymer linker and the active agent, and the bond between each polymer linker and the brain-internalizing transporter moiety, as well as any bond within the polymer linker itself.

[0086] In some embodiments, the first polymer linker is 500 to 10,000 Da, 600 to 9,500 Da, 700 to 9,000 Da, 800 to 8,500 Da, 800 to 6,000 Da, 800 to 5,000 Da, 800 to 4,000 Da, 800 to 3,000 Da, 800 to 2,000 Da, 900 to 8,000 Da, 1,000 to 7,000 Da, 1,500 to 6,500 Da, 2,000 to 6,000 Da, 3,000 to 6,000 Da, 4,000 Da, or 5,000 Da. and a molecular weight (MW) within a range selected from the group consisting of: 1,000 Da, 3,400 Da, 7,000 Da, 2,000 Da, 3,000 Da, 5,000 Da, 6,000 Da, 3,400 Da, 7,000 Da, 2,000 Da, 3,000 Da, 5,000 Da, 7,000 Da, 2,000 Da, 10,000 Da, 3,000 Da, 3,400 Da, 3,000 Da, 5,000 Da, 5,000 Da, 7,000 Da, 5,000 Da, 10,000 Da, and 7,000 Da. Each possibility represents a separate embodiment. According to some embodiments, the first polymer linker has a MW of at least 1,000 Da, at least 1,500 Da, at least 2,000 Da, at least 2,500 Da, at least 3,000 Da, at least 3,400 Da, at least 4,000 Da, at least 5,000 Da, at least 6,000 Da, at least 7,000 Da, or at least 8,000 Da. Each possibility represents a separate embodiment. According to some embodiments, the first polymer linker has a MW of up to 3,000 Da, up to 4,000 Da, up to 5,000 Da, up to 6,000 Da, up to 7,000 Da, or up to 10,000 Da. Each possibility represents a separate embodiment.

[0087] In some embodiments, the second polymer linker comprises a polymer selected from the group consisting of polyethers, polyacrylates, polyanhydrides, polyvinyl alcohols, polysaccharides, poly(N-vinylpyrrolidone), polyglycerin (PG), poly(N-(2-hydroxypropyl)methacrylamide), polyoxazolines, poly(amino acid)-based hybrids, recombinant polypeptides, derivatives, and combinations thereof. Each possibility represents a separate embodiment of the present invention.

[0088] In some embodiments, the second polymer linker comprises a polyether. In some embodiments, the second polymer linker is a polyether. In some embodiments, the polyether is polyethylene glycol (PEG) or a derivative thereof.

[0089] In some embodiments, the second polymer linker comprises a thiol (-SH) end group. In some embodiments, the second polymer linker is chemically bonded to the nanoparticle via the thiol (-SH) end group. In some embodiments, the second polymer linker is conjugated to the active agent via an amide bond. In some embodiments, the nanoparticle is bonded to the second polymer linker via a sulfide bond, and the active agent is conjugated to the second polymer linker via an amide bond. In some embodiments, the second polymer linker in the nanodelivery system has the structure -SR-CONH-, where R is a polymer chain composed of repeating monomer units. In other embodiments, the second polymer linker in the nanodelivery system has the structure -SR-NHCO-, where R is a polymer chain composed of repeating monomer units. In some embodiments, the second polymer linker is selected from thiolated PEG acid (HS-PEG-COOH) and thiolated PEG amine (HS-PEG-NH2). It should be understood that the HS and COOH / NH2 end groups refer to the polymer linker prior to conjugation with the nanoparticle and active agent. In some embodiments, the thiol group is chemically bonded to the core nanoparticle, and the acid or amine group is covalently conjugated to the active agent. In some embodiments, the second polymer linker in the nanodelivery system has a structure selected from -S-PEG-C(O)- and -S-PEG-NH-.

[0090] In some embodiments, the second polymer linker is a non-cleavable linker. In some embodiments, the second polymer linker is non-cleavable under physiological conditions.

[0091] In some embodiments, the second polymer linker has a molecular weight (MW) of 2,000 to 7,000 Da, 500 to 10,000 Da, 600 to 9,500 Da, 700 to 9,000 Da, 800 to 8,500 Da, 800 to 6,000 Da, 800 to 5,000 Da, 800 to 4,000 Da, 800 to 3,000 Da, 800 to 2,000 Da, 900 to 8,000 Da, 1,000 to 7,000 Da, 1,500 to 6,500 Da, 2,000 to 6,000 Da, 3,000 to 6,000 Da, 4,000 to 6,000 Da, or 1,000 to 2,000 Da. and 7,000 to 10,000 Da. Each possibility represents a separate embodiment. According to some embodiments, the second polymer linker has a MW of at least 1,000 Da, at least 2,000 Da, at least 3,000 Da, at least 4,000 Da, at least 5,000 Da, at least 6,000 Da, or at least 7,000 Da. Each possibility represents a separate embodiment. According to some embodiments, the second polymer linker has a MW of up to 2,000 Da, up to 3,000 Da, up to 4,000 Da, up to 5,000 Da, up to 6,000, up to 7,000 Da, or up to 10,000 Da. Each possibility represents a separate embodiment.

[0092] In some embodiments, the nanodelivery system comprises a bioactive molecule conjugated to a polymer, wherein the polymer comprises a cleavable linker. According to some embodiments, the cleavable linker comprises a bond susceptible to cleavage by an endogenous molecule localized or expressed in the brain. In some embodiments, the cleavable linker is PEG succinimidyl succinate (PEGSS). According to some embodiments, the endogenous molecule is glutathione. According to some embodiments, the endogenous molecule is selected from the group comprising a protease, a nuclease, a hydronium ion, and a reducing agent. Each possibility represents a separate embodiment.

[0093] According to some embodiments, the nanodelivery system further comprises a cleavage molecule inducer. According to some embodiments, the cleavage molecule inducer is selected from the group including N-acetyl-L-cysteine ​​(NAC), glutathione monoester, γ-glutamylcysteine, γ-glutamylcysteine ​​synthetase, and glutathione synthetase. Each possibility represents a separate embodiment.

[0094] In some embodiments, the endogenous molecule is glutathione and the cleavage molecule inducer is selected from the group including N-acetyl-L-cysteine ​​(NAC), glutathione monoester, γ-glutamylcysteine, γ-glutamylcysteine ​​synthetase, and glutathione synthetase.

[0095] According to some embodiments, the first polymer and the second polymer are different polymers. In some embodiments, the first polymer and the second polymer comprise the same polymer. In further embodiments, the first polymer linker is composed of repeating monomer units, and the second polymer linker is composed of the same repeating monomer units as the first linear polymer linker. In some related embodiments, the first linear polymer linker has a different number of repeating monomer units than the second linear polymer linker.

[0096] In some embodiments, the first and second polymer linkers comprise the same polymer selected from the group consisting of polyethers, polyacrylates, polyanhydrides, polyvinyl alcohols, polysaccharides, poly(N-vinylpyrrolidone), polyglycerol (PG), poly(N-(2-hydroxypropyl)methacrylamide), polyoxazolines, poly(amino acid)-based hybrids, recombinant polypeptides, derivatives, and combinations thereof. In some embodiments, both the first and second polymer linkers comprise PEG. In some embodiments, both the first and second polymer linkers are PEG. In some embodiments, both the first and second polymer linkers comprise thiolated PEG. In some embodiments, the first and second polymer linkers comprise thiolated PEG acid (HS-PEG-COOH) or thiolated PEG amine (HS-PEG-NH2). In some embodiments, the first and second polymer linkers are thiolated PEG acid (HS-PEG-COOH) or thiolated PEG amine (HS-PEG-NH2). In some embodiments, the first and second polymer linkers are both thiolated PEG acid (HS-PEG-COOH). In some embodiments, the first and second polymer linkers are both thiolated PEG amine (HS-PEG-NH2).

[0097] In some embodiments, the first and second polymer linkers are linear. In accordance with the principles of the present invention, the first and second linear polymer linkers have substantially different lengths.

[0098] In some embodiments, the term "length" of a polymer segment or linker refers to the length of the polymer, which depends on the number of monomers incorporated therein, the length of each monomer unit, the structure of the polymer chain (e.g., whether the polymer is linear or branched), spatial conformation, valence angle (or bond angle) distortion, and the degree of stretching or winding.

[0099] The length of a polymer can be calculated as known in the art, for example, as described in Chapter 3 of Introduction to Physical Polymer Science, 4th Edition, L.H. Sperling, first published November 4, 2005. Additionally, various computer modeling methods, such as those using Hyperchem, ACD / 3D, MOE 2010.10, or Chem 3D software, among others, can be used to estimate the length of a polymer, as known in the art. Physical characterization methods, such as static light scattering, can also be used to estimate the length of a coiled polymer. It should be understood that when assessing the difference in length between a first polymer linker and a second polymer linker, the same length definition (or length measurement method) must be used for both polymer linkers.

[0100] When referring to a linear polymer, the term "length" can refer to different definitions of length. According to some embodiments, the term "length" refers to the displacement length, also referred to herein as the "end-to-end" length, which is the distance between the two ends of the polymer chain of a coiled polymer. The end-to-end length is, for example, the Flory radius:

number

[0101] According to some embodiments, the term "length" refers to the path length, which is the distance between the ends of a polymer chain when the polymer is stretched. The path length can be considered the maximum possible displacement length. The path length (also referred to herein as the "old path length") can be calculated by dividing the MW of the polymer by the MW of the monomer unit and multiplying by the length of the monomer unit. To account for bond angles, the path length (also referred to herein as the "new path length") can be calculated by dividing the MW of the polymer by the MW of the monomer unit and multiplying by the length of the monomer unit, and then multiplying by the cosine of ((bond angle θ-180) / 2).

[0102] As explained above, the length of a linear polymer can be estimated based on its molecular weight and the chemical structure of its monomer units. To evaluate the difference in length between a first linear polymer linker and a second polymer linker that contain the same polymer (i.e., the same type but composed of different numbers of monomer units), the molecular weight of the two polymer linkers can be conveniently used. Thus, in some embodiments, the first and second linear polymer linkers have substantially different molecular weights. As used herein, the term "substantially different" refers to a difference of at least 5%, at least 6%, at least 7%, at least 8%, at least 9%, at least 10%, at least 12%, at least 15%, at least 18%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, or at least 50%. Each possibility represents a separate embodiment of the present invention.

[0103] In some embodiments, the monomer units of the first polymer linker and the monomer units of the second polymer linker have substantially similar molecular weights. As used herein, the term "substantially similar" refers to a degree of similarity of at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, or at least 95%. Each possibility represents a separate embodiment of the present invention.

[0104] In some embodiments, the first polymer linker and the second polymer linker comprise similar polymers. In some embodiments, the first linear polymer linker is composed of repeating monomer units, and the second linear polymer linker is composed of the same repeating monomer units as the first linear polymer linker, but the first linear polymer linker has a different number of repeating monomer units than the second linear polymer linker. In some embodiments, the first polymer linker and the second polymer linker are similar except for the length of the first polymer linker and the second polymer linker.

[0105] In some embodiments, the first and second linear polymer linkers have a difference in their respective molecular weights of at least about 100 Da, at least about 150 Da, at least about 200 Da, at least about 250 Da, at least about 300 Da, at least about 350 Da, at least about 400 Da, at least about 450 Da, at least about 500 Da, at least about 550 Da, at least about 600 Da, at least about 650 Da, at least about 700 Da, at least about 750 Da, at least about 800 Da, at least about 850 Da, at least about 900 Da, at least about 950 Da, at least about 1000 Da, at least about 1100 Da, at least about 1200 Da, at least about 1300 Da, at least about 1400 Da, or at least about 1500 Da. Each possibility represents a separate embodiment of the present invention.

[0106] In some embodiments, the difference in length between the first and second linear polymer linkers is configured to allow the brain-internalizing transporter moiety to be exposed on the outer surface of the nanodelivery system facing the BBB. It should be understood that the active agent is not encapsulated within the nanoparticle core, but rather is attached to its outer surface via a polymer linker, similar to the brain-internalizing moiety attached to the surface of the same nanoparticle core via a polymer linker. Such core-shell structures, which can be formed by a relatively simple preparation process, however, presented an unexpected obstacle: when the same type and molecular weight of polymer linkers were used to conjugate the brain-internalizing moiety and the active agent, the BBB penetration efficiency of such delivery systems was very low. While not wishing to be bound by theory or mechanism of action, it is believed that polymer chains of similar lengths did not provide sufficient exposure of the brain-internalizing moiety on the outer surface of the delivery system. To overcome this obstacle, polymer linkers of different lengths were used to conjugate the brain-internalizing moiety and the active agent. Surprisingly, the inventors of the present invention have found that when both polymer linkers are composed of the same monomer units, a higher molecular weight for the first polymer linker than that of the second polymer linker enables the delivery of active agents of different structures and sizes, including antibodies, peptides, and small molecules, into the brain. Without wishing to be bound by theory or mechanism of action, it is believed that the higher MW first polymer linker has both greater path length and end-to-end distance than the second polymer linker, thus allowing exposure of brain-internalizing transporter moieties and / or shielding of the active agent, providing permeability through the BBB. Nanodelivery systems comprising a first polymer linker with a higher length and / or MW than the second polymer linker therefore provide a versatile BBB-permeable platform for the delivery of various bioactive molecules or labeling moieties.

[0107] Without wishing to be bound by any theory or mechanism of action, it is believed that the active agent remains accessible and active despite being attached to the delivery system, rather than being enclosed or encapsulated within the nanoparticle core. It was unexpectedly discovered that an antibody conjugated to a polymer linker attached to a nanoparticle via a stable, non-cleavable covalent bond retained its activity and functionality. It was even more surprising that a peptide targeting amyloid-β plaques, conjugated to a polymer linker attached to a nanoparticle, retained its targeting ability in the brain despite being at least partially shielded by insulin conjugated to a polymer linker longer than the peptide. Thus, the specific composition of the nanodelivery system of the present invention, which ensures the formation of conjugated particles with a specific hierarchical structure, not only enables the delivery of various types of active agents, but also does not interfere with the functionality of the active agent, so that cleavage of the bond between the active agent and the nanoparticle after penetration through the BBB is not necessarily required.

[0108] Thus, in some embodiments, the molecular weight of the first polymer linker is higher than the molecular weight of the second polymer linker. In some embodiments, the molecular weight of the first polymer linker is higher than the molecular weight of the second polymer linker, provided that the molecular weight of the second polymer linker is less than 4950 Da. In some embodiments, the molecular weight of the first polymer linker is higher than the molecular weight of the second polymer linker, provided that the molecular weight of the second polymer linker is less than 4900 Da. In some embodiments, the molecular weight of the first polymer linker is higher than the molecular weight of the second polymer linker, provided that the molecular weight of the second polymer linker is less than 4800 Da. In some embodiments, the molecular weight of the first polymer linker is higher than the molecular weight of the second polymer linker, provided that the molecular weight of the second polymer linker is less than 4780 Da. In some embodiments, the first polymer linker is a PEG derivative having a molecular weight of about 5 kDa, and the second polymer linker is a PEG derivative having a molecular weight of about 3500 kDa.

[0109] In some embodiments, the first polymer linker has a molecular weight higher than that of the second polymer linker. In some embodiments, the MW of the first and second polymer linkers is directly dependent on the relative molecular weights of the biologically active molecule and the brain-internalizing moiety. In some embodiments, the biologically active molecule has a higher MW than the brain-internalizing moiety, and the first polymer linker has a higher MW than the second polymer linker.

[0110] In some embodiments, the first polymer linker is longer than the second polymer linker. In some embodiments, the first polymer linker has a higher end-to-end distance than the second polymer linker. In some embodiments, the first polymer linker has a higher path distance than the second polymer linker.

[0111] In some embodiments, the first polymer linker has a MW smaller than the molecular weight of the second polymer linker. In some related embodiments, the second polymer linker has a MW of at least about 4000 Da, and the difference in MW between the first and second polymer linkers is at least about 2000 Da. In further embodiments, the second polymer linker has a MW of at least about 4500 Da, and the difference in MW between the first and second polymer linkers is at least about 2500 Da. In yet further embodiments, the second polymer linker has a MW of at least about 4700 Da, and the difference in MW between the first and second polymer linkers is at least about 3000 Da. Without wishing to be bound by theory or mechanism of action, it is believed that a significantly longer second linker allows for folding (or a higher degree of coiling) of the polymer chain, such that the actual distance between the bioactive molecule and the nanoparticle core is smaller than between the brain-internalizing portion and the nanoparticle core, such that the bioactive molecule is at least partially shielded by the brain-internalizing portion exposed on the surface of the delivery system during BBB penetration. In some related embodiments, the end-to-end distance of the first polymer linker is higher than the end-to-end distance of the second polymer linker, despite the higher MW of the second polymer linker.

[0112] In some embodiments, the distance between the biologically active molecule and the nanoparticle core is smaller than the distance between the brain-internalizing moiety and the nanoparticle core. In some embodiments, at least one end group of the first polymer linker is the same as at least one end group of the second polymer linker. In some embodiments, at least one functional end group of the first polymer linker is the same as at least one functional end group of the second polymer linker. In some embodiments, both end groups of the first polymer linker are the same as both end groups of the second polymer linker. In some embodiments, both functional end groups of the first polymer linker are the same as both functional end groups of the second polymer linker.

[0113] In some embodiments, the nanoparticles are linked to an additional third polymer. In some embodiments, the polymer is a monofunctional polymer linker. In some embodiments, the nanoparticles are coated with a polymer layer comprising a first polymer linker, a second polymer linker, and an additional third polymer linker, wherein the additional polymer linker is monofunctional. The terms "third polymer" and "third polymer linker" may be used interchangeably. In some embodiments, the third polymer functions as a spacer moiety. In some embodiments, the third polymer linker is a linear polymer linker. In some embodiments, the third polymer is selected from the group consisting of polyethers, polyacrylates, polyanhydrides, polyvinyl alcohols, polysaccharides, poly(N-vinylpyrrolidone), polyglycerin (PG), poly(N-(2-hydroxypropyl)methacrylamide), polyoxazolines, poly(amino acid)-based hybrids, recombinant polypeptides, derivatives, and combinations thereof.

[0114] As used herein, the term "monofunctional" means that the polymer, prior to being conjugated to a nanoparticle, has only one functional group configured to link said polymer to the nanoparticle. A monofunctional polymer linker is therefore not conjugated and cannot conjugate any moiety other than the nanoparticle.

[0115] In some embodiments, the third polymer comprises the same monomer units as the first and / or second polymer. In some embodiments, the third polymer is attached to the nanoparticle via the thiol end group of the polymer. In some embodiments, the third polymer is a polyether. In some embodiments, the polyether is methoxypolyethylene glycol (mPEG) or a derivative thereof. In some embodiments, the mPEG is thiolated (mPEG-SH), and the thiolated mPEG is attached to the core nanoparticle via the thiol end group.

[0116] In some embodiments, the third polymer has a MW of 1,000 to 7,000 Da. In some embodiments, the third polymer has a MW of 500 to 1,000 Da, 500 to 3,000 Da, 500 to 7,000 Da, 500 to 10,000 Da, 1,000 to 3,000 Da, 1,000 to 5,000 Da, 1,000 to 7,000 Da, 1,000 to 10,000 Da, 3,000 to 5,000 Da, 3,000 to 7,000 Da, 3,000 to 10,000 Da, or 7,000 to 10,000 Da. Each possibility represents a separate embodiment. According to some embodiments, the third polymer has a MW of at least 1,000 Da, at least 2,000 Da, at least 3,000 Da, at least 4,000 Da, at least 5,000 Da, at least 6,000 Da, at least 7,000 Da, or at least 8,000 Da. Each possibility represents a separate embodiment. According to some embodiments, the third polymer has a MW of up to 1,000 Da, up to 2,000 Da, up to 3,000 Da, up to 4,000 Da, up to 5,000 Da, up to 6,000 Da, up to 7,000 Da, or up to 10,000 Da. Each possibility represents a separate embodiment.

[0117] In some embodiments, the v / v ratio of the third polymer in the shell is 10-90%. In some embodiments, the v / v ratio of the third polymer in the shell is 10-20%, 10-50%, 10-70%, 10-90%, 20-50%, 20-70%, 20-90%, 50-70%, 50-90%, or 70-90%. Each possibility represents a separate embodiment. In some embodiments, the v / v ratio of the third polymer in the shell is less than 20%, less than 40%, less than 50%, less than 70%, or less than 90%. Each possibility represents a separate embodiment.

[0118] In some embodiments, the length of the third polymer is substantially similar to the length of the first polymer linker or the second polymer linker. In some embodiments, the length of the third polymer is substantially similar to the length of the first polymer linker. In some embodiments, the length of the third polymer is substantially similar to the length of the second polymer linker. In some embodiments, the length of the third polymer is substantially similar to the length of the polymer linker (first or second) whose length is higher than the length of the other polymer linker. In some embodiments, the molecular weight of the third polymer is substantially similar to the molecular weight of the first polymer linker or the second polymer linker. In some embodiments, the molecular weight of the third polymer is substantially similar to the molecular weight of the first polymer linker. In some embodiments, the molecular weight of the third polymer is substantially similar to the molecular weight of the second polymer linker. In some embodiments, the molecular weight of the third polymer is substantially similar to the molecular weight of the polymer linker (first or second) that has a higher molecular weight than the other polymer linker.

[0119] Without wishing to be bound by any theory or mechanism of action, the efficacy of the nanodelivery system of the present invention also depends on the molar ratio of different polymer linkers, which dictates the density of brain-internalizing transporter moieties and active agents within the delivery system.

[0120] In some embodiments, the first polymer linker comprises about 5-70% mol, 5-60% mol, 8-60% mol, 10-60% mol, 10-50% mol, 10-40% mol, 10-30% mol, 10-25% mol, 10-20% mol, 15-50% mol, 15-40% mol, 15-30% mol, 15 ... Constitutes 5-20% mol, 2-10% mol, 2-20% mol, 2-50% mol, 2-60% mol, 2-70% mol, 5-10% mol, 5-20% mol, 5-70% mol, 10-20% mol, 10-50% mol, 10-70% mol, 30-50% mol, 30-60% mol, 30-70% mol, 50-60% mol, or 50-70% mol. Each possibility represents a separate embodiment of the present invention. In some embodiments, the first polymer linker comprises at least 2%, at least 4%, at least 5%, at least 6%, at least 8%, at least 10%, at least 12%, at least 15%, at least 18%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 50%, or at least 60% of the total polymer attached to the nanoparticle, with each possibility representing a separate embodiment.

[0121] In some embodiments, the second polymer linker comprises about 5-70% mol, 5-60% mol, 10-60% mol, 10-55% mol, 10-50% mol, 10-40% mol, 10-30% mol, 10-25% mol, 10-20% mol, 15-60% mol, 15-55% mol, 15-50% mol, 15-45% mol, 15-40% mol, 15-30% mol, 15-45% mol, 15-50% mol, 15-45% mol, 15-50% mol, 15-30% mol, 15-40% mol, 15-50% mol, 15-60% mol, 15-60% mol, 15-55% mol, 15-50% mol, 15-45% mol, 15-40% mol, 15-30% mol, 15-40% mol, 15-50% mol, 15-60% mol, 15-50% mol, 15-40% mol, 15-30% mol, 15-40% mol, 15-5 ...50% mol, 15-40% mol, 15-30% mol, 1 Constitutes 5-25% mol, 15-20% mol, 2-10% mol, 2-20% mol, 2-50% mol, 2-60% mol, 2-70% mol, 5-10% mol, 5-20% mol, 10-20% mol, 10-50% mol, 10-70% mol, 20-50% mol, 20-40% mol, 30-50% mol, 30-60% mol, 30-70% mol, 50-60% mol, or 50-70% mol. Each possibility represents a separate embodiment of the present invention. In some embodiments, the second polymer linker comprises at least 2%, at least 4%, at least 5%, at least 6%, at least 8%, at least 10%, at least 12%, at least 15%, at least 18%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 50%, or at least 60% of the total polymer attached to the nanoparticle, with each possibility representing a separate embodiment.

[0122] In some embodiments, the third polymer comprises approximately 5-90% mol, 5-85% mol, 5-80% mol, 10-80% mol, 20-78% mol, 25-75% mol, 30-75% mol, 40-75% mol, 50-75% mol, 60-75% mol, 60-70% mol, 60-80% mol, 5-60% mol, 10-60% mol, 10-55% mol, 10-50% mol, 10-40% mol, 15-60% mol, 15-55% mol, 15-50% mol, 15-45% mol, or 15-40% mol of the total polymer bound to the nanoparticles. Each possibility represents a separate embodiment of the present invention. In some embodiments, the third polymer comprises 60-80% mol of the total polymer bound to the nanoparticles. In some embodiments, the third polymer comprises 50-80% mol of the total polymer bound to the nanoparticles. In some embodiments, the third polymer comprises at least 2%, at least 4%, at least 5%, at least 6%, at least 8%, at least 10%, at least 12%, at least 15%, at least 18%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, or at least 70% mol of the total polymer bound to the nanoparticles. Each possibility represents a separate embodiment.

[0123] In some embodiments, the first polymer linker comprises about 15-45% mol, the second polymer linker comprises about 10-45% mol, and the third polymer comprises about 40-75% mol of the total polymer attached to the nanoparticle.

[0124] It should be understood that the % mol of each polymer moiety is dependent upon the other polymer moieties attached to the nanoparticles such that the total % mol of polymer does not exceed 100%.

[0125] In some embodiments, the first polymer linker, the second polymer linker, and the third polymer are in a (w / w / w) ratio of at least 5:5:90 to 60:30:30.

[0126] In some embodiments, the first polymer and the second polymer are in a (w / w) ratio of at least 40:60 to 95:5.

[0127] In accordance with the principles of the present invention, a nanodelivery system comprises a brain-internalizing transporter moiety conjugated to a first polymer linker. The term "brain-internalizing transporter moiety" may be used interchangeably herein with the term "brain-internalizing moiety" and refers to a molecule capable of specifically binding to a receptor or surface protein expressed by a cellular component of the BBB. The three major cellular components of the brain microvasculature that collectively form the BBB are brain endothelial cells, astrocyte endfeet, and pericytes (PCs). In some embodiments, the brain-internalizing transporter moiety can bind to a receptor or surface protein expressed by brain endothelial cells. In some embodiments, the brain-internalizing transporter moiety can bind to a receptor or surface protein expressed by astrocyte endfeet. In some embodiments, the brain-internalizing transporter moiety can bind to a receptor or surface protein expressed by pericytes (PCs). Without wishing to be bound by any theory or mechanism, it is hypothesized that the brain-internalizing moiety facilitates transport of the entire nanodelivery system across the BBB, possibly via receptor-mediated transcytosis (RMT) or receptor-mediated endocytosis (RME) mechanisms.

[0128] In some embodiments, the brain-internalizing moiety is selected from, but is not limited to, insulin, an antibody specific for the insulin receptor, transferrin, an antibody specific for the transferrin receptor, a polypeptide that specifically binds to the transferrin receptor, a polypeptide that specifically binds to the insulin receptor, insulin-like growth factor 1, an antibody specific for insulin-like growth factor receptor 1, a polypeptide that specifically binds to insulin-like growth factor receptor 1, apolipoprotein A1, B, or E, lactoferrin, angiopep-2, an antibody specific for low-density lipoprotein receptor or lipoprotein receptor-related protein, a polypeptide that specifically binds to low-density lipoprotein receptor or lipoprotein receptor-related protein, an antibody specific for the diphtheria toxin receptor, a polypeptide that specifically binds to the diphtheria toxin receptor, and a BBB-permeable cell-penetrating peptide (CPP). Each possibility represents a separate embodiment of the present invention. As used herein, the term "cell-penetrating peptide (CPP)" refers to a peptide with enhanced ability to cross cell membrane bilayers without causing significant, lethal membrane damage. The term "BBB-permeable CPP" refers to a cell-penetrating peptide that can cross the membrane of BBB cells and thus penetrate into the brain (Zou, Li-li et al., Current neuropharmacology 11.2 (2013): 197-208. and Stalmans, Sofie et al., PloS one 10.10 (2015): e0139652.).

[0129] Other cellular proteins known in the art that can promote transcytosis can also be used as brain-internalizing moieties. In some embodiments, the brain-internalizing moiety is selected from the group consisting of insulin, transferrin, low-density lipoprotein, apolipoprotein A1, B, or E, and lactoferrin. Each possibility represents a separate embodiment of the present invention. In some embodiments, the brain-internalizing moiety is selected from the group consisting of insulin and transferrin. In some embodiments, the brain-internalizing moiety is insulin. In some embodiments, the molecular weight (MW) of insulin is about 5 kilodaltons (kD).

[0130] In some embodiments, the v / v ratio of the brain-internalizing moiety (e.g., insulin) within the shell is 2-10%, 2-20%, 2-50%, 2-60%, 2-70%, 5-10%, 5-20%, 5-50%, 5-60%, 5-70%, 10-20%, 10-50%, 10-60%, 10-70%, 30-50%, 30-60%, 30-70%, 50-60%, or 50-70%. In some embodiments, the v / v ratio of insulin within the shell is 5-60%. In some embodiments, the v / v ratio of insulin within the shell is at least 2%, at least 5%, at least 10%, at least 30%, at least 50%, at least 60%, or at least 70%. Each possibility represents a separate embodiment.

[0131] According to the principles of the present invention, the second polymer linker is conjugated to an active agent selected from a biologically active molecule and a labeling molecule. The term "active agent" as used herein refers to an agent intended to be delivered into the brain of a subject and capable of being used as a therapeutic or diagnostic agent. In some embodiments, the active agent is characterized by poor BBB permeability. In some embodiments, upon penetration of the BBB, the active agent can further target the nanodelivery system to specific regions in the brain, such as the hippocampus, striatum, cerebellum, and cortex. In some embodiments, upon penetration of the BBB, the active agent can target the nanodelivery system to specific cell populations in the brain, such as glioma cells, microglial cells, and neuronal cells.

[0132] In some embodiments, the active agent is a macromolecule. As defined herein, the term "macromolecule" refers to a very large molecule, usually formed through polymerization of monomers. In some embodiments, the macromolecule is a protein. In some embodiments, the macromolecule is an enzyme.

[0133] In some embodiments, the macromolecule is an antibody. As used herein, the term "antibody" refers to a polypeptide or group of polypeptides containing at least one binding domain formed by folding of a polypeptide chain, with a three-dimensional binding space with an internal surface shape and charge distribution complementary to the antigenic determinant characteristics of the antigen. Antibodies typically have a tetrameric form, comprising two identical pairs of polypeptide chains, each pair having one "light" chain and one "heavy" chain. The variable regions of each light / heavy chain pair form the antibody binding site. Antibodies may be oligoclonal, polyclonal, monoclonal, chimeric, camelized, CDR-grafted, multispecific, bispecific, catalytic, humanized, fully human, anti-idiotypic, and antibodies that can be labeled in soluble or bound form, as well as fragments, variants, or derivatives thereof, including epitope-binding fragments, alone or in combination with other amino acid sequences. Antibodies may be derived from any species. The term antibody also includes binding fragments, including, but not limited to, Fv, Fab, Fab', F(ab')2 single-chain antibodies (svFC), dimeric variable regions (diabodies), and disulfide-linked variable regions (dsFv). Specifically, antibodies include immunoglobulin molecules and immunologically active fragments of immunoglobulin molecules, i.e., molecules that contain an antigen-binding site. Antibody fragments may or may not be fused to another immunoglobulin domain, including, but not limited to, an Fc region or fragment thereof. Those skilled in the art will further appreciate that other fusion products may be produced, including, but not limited to, scFv-Fc fusions, variable region (e.g., VL and VH) to Fc fusions, and scFv-scFv-Fc fusions.

[0134] In some embodiments, the active agent conjugated to the second polymer linker is a biologically active molecule. In some embodiments, the biologically active molecule is adjacent to the second polymer linker. As used herein, the term "biologically active molecule" refers to a compound or molecule that can induce or modify a biological response in a system. In some embodiments, the biologically active molecule is a therapeutic agent. In some embodiments, the biologically active molecule has therapeutic applications. In some embodiments, the biologically active molecule has diagnostic applications. In some embodiments, the biologically active molecule has both therapeutic and diagnostic applications.

[0135] In some embodiments, the bioactive molecule comprises a small molecule, a polymer, an oligonucleotide, an antisense RNA, a peptide, or any combination thereof. In some embodiments, the bioactive molecule is selected from the group consisting of a polymer, a peptide, and a small molecule. In some embodiments, the bioactive molecule is selected from the group consisting of an antibody, a peptide, and a small molecule. Each possibility represents a separate embodiment of the present invention.

[0136] As used herein, the term "peptide" refers to any polymeric compound produced by the formation of an amide bond between the α-carboxyl group of one D- or L-amino acid and the α-amino group of another D- or L-amino acid.

[0137] As used herein, the term "small molecule" refers to a synthetic or naturally occurring organic or inorganic molecule that generally has a molecular weight of less than 1000 Da. The term "small molecule" also encompasses any fragment of a peptide, protein, or antibody, including native sequences and variants within the above molecular weight range.

[0138] In some embodiments, the bioactive molecule is a therapeutic agent effective in treating a brain-related disease or disorder, hi some embodiments, the bioactive molecule is an antibody used in the treatment or diagnosis of a brain-related disease.

[0139] As used herein, the term "brain-related disease or disorder" refers to any disease or disorder that causes dysfunction of the brain or any of its cells. Non-limiting examples of brain-related diseases and disorders are neurodegenerative disorders such as Parkinson's disease, Alzheimer's disease, Huntington's disease, and dementia; neuromuscular diseases such as amyotrophic lateral sclerosis (ALS) and motor neuron disease; neurodevelopmental diseases such as autism spectrum disorder and attention deficit hyperactivity disorder (ADHD); autoimmune brain-related diseases such as multiple sclerosis (MS); neuropsychiatric disorders such as schizophrenia, drug addiction, smoking addiction, eating disorders, obsessive-compulsive disorder, various forms of depression, anxiety, cognitive disorders, and affective disorders; seizure disorders such as epilepsy; pain disorders such as migraine; cerebrovascular disorders including traumatic brain injury and stroke; brain-related cancers such as brain tumors and neural tumors, brain metastases, glioma, glioblastoma (GBM), and gliosarcoma (GS); neurodevelopmental diseases such as Huntington's disease, Kennedy disease, metabolic disorders, lysosomal storage diseases, and Duchenne; and neuroinfectious diseases.

[0140] In some embodiments, the active agent is a labeled molecule. As used herein, the term "labeled molecule" refers to a molecule capable of generating a signal detectable by a suitable detection means, such as, but not limited to, radioactive molecules and fluorescent molecules. In some embodiments, the labeled molecule has diagnostic applications. In some embodiments, the labeled molecule is a diagnostic agent. In some embodiments, the labeled molecule comprises a small molecule, a polymer, an oligonucleotide, an antisense RNA, a peptide, or any combination thereof. In some embodiments, the labeled molecule is a small molecule. In some embodiments, the labeled molecule is an antibody.

[0141] In some embodiments, the active agent is an antibody having a molecular weight (MW) of 100-120 kD, 100-150 kD, 100-200 kD, 100-250 kD, 150-200 kD, 150-250 kD, or 200-250 kD. Each possibility represents a separate embodiment. In some embodiments, the antibody has a MW of at least 100 kD, at least 110 kD, at least 120 kD, at least 130 kD, at least 140 kD, at least 150 kD, at least 160 kD, at least 180 kD, at least 200 kD, or at least 250 kD. Each possibility represents a separate embodiment. In some embodiments, the antibody has a MW of 150-200 kD. In some embodiments, the antibody has a MW of 130-180 kD. In some embodiments, the antibody has a MW of 140-160 kD.

[0142] In some embodiments, the antibody has a MW of 150-200 kD and the second polymer linker (PEG) has a MW of at least 2,000 Da, at least 2,500 Da, or at least 3,000 Da. In some embodiments, the antibody has a MW of 150-200 kD and the second polymer linker (PEG) has a MW of at most 2,000 Da, at most 2,500 Da, at most 3,000 Da, at most 3,500 Da, at most 4,000 Da, at most 5,000 Da, or at most 6,000 Da. In some embodiments, the brain-internalizing moiety is insulin with a MW of 5-6 kD and the first polymer linker has a MW of at least 2,000 Da, at least 2,500 Da, at least 3,000 Da, at least 3,400 Da, at least 4,000 Da, or at least 4,500 Da.

[0143] In some embodiments, the v / v ratio of antibody in the shell is 2-10%, 2-20%, 2-30%, 2-40%, 5-10%, 5-20%, 5-30%, 5-40%, 10-20%, 10-30%, 10-40%, 20-30%, 20-40%, or 30-40%. In some embodiments, the v / v ratio of antibody in the shell is 5-30%. In some embodiments, the v / v ratio of antibody in the shell is at least 2%, at least 5%, at least 10%, at least 30%, or at least 40%. Each possibility represents a separate embodiment.

[0144] In some embodiments, the v / v ratio of polymer in the shell is 2-10%, 2-20%, 2-30%, 2-40%, 5-10%, 5-20%, 5-30%, 5-40%, 10-20%, 10-30%, 10-40%, 20-30%, 20-40%, or 30-40%. In some embodiments, the v / v ratio of polymer in the shell is 5-30%. In some embodiments, the v / v ratio of polymer in the shell is at least 2%, at least 5%, at least 10%, at least 30%, or at least 40%. Each possibility represents a separate embodiment.

[0145] In some embodiments, the active agent has a MW of less than 1,000 Daltons (Da). In some embodiments, the active molecule has a MW of 10-50 Da, 10-100 Da, 10-500 Da, 10-1,000 Da, 50-100 Da, 50-500 Da, 50-1,000 Da, 100-300 Da, 100-500 Da, 100-800 Da, 100-1,000 Da, 500-800 Da, 500-1,000 Da, or 800-1,000 Da. Each possibility represents a separate embodiment.

[0146] In some embodiments, the active agent has a MW of less than 1,000 Da, less than 900 Da, less than 800 Da, less than 700 Da, less than 600 Da, less than 500 Da, less than 400 Da, less than 300 Da, less than 200 Da, or less than 100 Da. Each possibility represents a separate embodiment. In some embodiments, the active agent has a MW of greater than 100 Da, greater than 200 Da, greater than 300 Da, greater than 400 Da, greater than 500 Da, greater than 600 Da, greater than 700 Da, greater than 800 Da, or greater than 900 Da. Each possibility represents a separate embodiment.

[0147] In some embodiments, the active agent is a small molecule. In some embodiments, the bioactive molecule is a small molecule. In some embodiments, the bioactive molecule is an oligonucleotide. In some embodiments, the bioactive molecule is an antisense RNA. In some embodiments, the bioactive molecule is a peptide. In some embodiments, the bioactive molecule is a drug.

[0148] In some embodiments, the v / v ratio of the bioactive molecule within the shell is 40-95%. In some embodiments, the v / v ratio is 30-40%, 30-50%, 30-70%, 30-90%, 30-95%, 30-98%, 40-50%, 40-70%, 40-90%, 40-95%, 40-98%, 60-70%, 60-90%, 60-95%, 60-98%, 70-90%, 70-95%, 70-98%, 80-90%, 80-95%, or 80-98%. Each possibility represents a separate embodiment.

[0149] According to some embodiments, the inorganic nanoparticles are gold nanoparticles. According to some embodiments, the first linear polymer linker is a thiolated PEG5000 acid or a thiolated PEG5000 amine. According to some embodiments, the second linear polymer linker is a thiolated PEG3500 acid or a thiolated PEG3500 amine. According to some embodiments, the brain internalization transporter moiety is insulin. The nanodelivery system may further comprise an active agent selected from an antibody, a peptide, and a small molecule.

[0150] According to some embodiments, the inorganic nanoparticles are iron oxide nanoparticles. According to some embodiments, the first linear polymer linker is a thiolated PEG5000 acid or a thiolated PEG5000 amine. According to some embodiments, the second linear polymer linker is a thiolated PEG3500 acid or a thiolated PEG3500 amine. According to some embodiments, the brain internalization transporter moiety is insulin. The nanodelivery system may further comprise an active agent selected from an antibody, a peptide, and a small molecule.

[0151] According to some embodiments, the inorganic nanoparticles are gold nanoparticles. According to some embodiments, the first linear polymer linker is a thiolated PEG5000 acid or a thiolated PEG5000 amine. According to some embodiments, the second linear polymer linker is a thiolated PEG3500 acid or a thiolated PEG3500 amine. According to some embodiments, the brain internalization transporter moiety is transferrin. The nanodelivery system may further comprise an active agent selected from an antibody, a peptide, and a small molecule.

[0152] According to some embodiments, the inorganic nanoparticles are gold nanoparticles. According to some embodiments, the first linear polymer linker is a thiolated PEG1000 acid or a thiolated PEG1000 amine. According to some embodiments, the second linear polymer linker is a thiolated PEG5000 acid or a thiolated PEG5000 amine. According to some embodiments, the brain-internalizing transporter moiety is insulin. The nanodelivery system may further comprise an active agent selected from an antibody, a peptide, and a small molecule.

[0153] Preparation Process According to another aspect, there is provided a process for the preparation of the nanodelivery system of the present invention in all its embodiments as described above, the process comprising sequentially: a) partially coating the surface of inorganic nanoparticles with a first linear polymer linker, and then conjugating said first linear polymer linker to a brain-internalizing transporter moiety; b) partially coating the surface of the inorganic nanoparticles with a second linear polymer linker, followed by conjugating said second linear polymer linker to an active agent; Including, Steps (a) and (b) may be performed in any order.

[0154] As used herein, the term "partially coating" refers to conjugating a plurality of individual polymer linkers to the surface of a nanoparticle such that the plurality of linkers partially cover the surface of the nanoparticle at a density level that is lower than the saturation level of a bare nanoparticle.

[0155] Any method known in the art can be used to determine the amount of polymer needed to achieve full density (i.e., 100%) coating of nanoparticles, and therefore the amount needed for partial coating. For example, adding different amounts of polymer to a nanoparticle solution and measuring the concentration of free polymer in the supernatant after centrifugation is a widely used method. Alternatively, any characterization method sensitive to changes in coating density, such as zeta potential and DLS, can be used. Furthermore, theoretical calculations can be performed to determine the amount of polymer needed to achieve complete coating according to the surface area of ​​the nanoparticles. For example, thiol-PEG molecules can be applied to a 0.35 nm surface of a gold nanoparticle. 2 It has previously been shown that the thiol-PEG linker occupies a footprint area of ​​100% of the gold nanoparticle surface (Qian, Ximei, et al., Nature biotechnology 26.1 (2008): 83-90). Therefore, the amount of thiol-PEG linker required to cover 100% of the surface of the gold nanoparticles can be calculated based on the average diameter of the GNPs.

[0156] In some embodiments, the first linear polymer linker and the second linear polymer linker are each added in an amount suitable to cover 5% to 60% of the surface of the inorganic nanoparticle.

[0157] In some embodiments, step (a) comprises coating 5%-60%, 10-60%, 10-50%, 10-40%, 10-30%, 10-25%, 10-20%, 15-50%, 15-40%, 15-30%, 15-25%, 15-20%, 2-10%, 2-20%, 2-50%, 2-60%, 2-70%, 5-10%, 5-20%, 5-70%, 10-20%, 10-50%, 10-70%, 30-50%, 30-60%, 30-70%, 50-60%, or 50-70% of the surface of the inorganic nanoparticles.

[0158] In some embodiments, step (b) comprises coating 5%-60%, 10-60%, 10-50%, 10-40%, 10-30%, 10-25%, 10-20%, 15-50%, 15-40%, 15-30%, 15-25%, 15-20%, 2-10%, 2-20%, 2-50%, 2-60%, 2-70%, 5-10%, 5-20%, 5-70%, 10-20%, 10-50%, 10-70%, 30-50%, 30-60%, 30-70%, 50-60%, or 50-70% of the surface of the inorganic nanoparticles.

[0159] In some embodiments, the process further comprises partially coating the surface of the inorganic nanoparticles with a third polymer linker, wherein said polymer linker is a monofunctional linker.

[0160] In some embodiments, step (a) occurs before step (b). In some embodiments, the process further comprises centrifugation between step (a) and step (b). In other embodiments, step (a) occurs after step (b). In some embodiments, the process further comprises centrifugation between step (b) and step (a). In some embodiments, the active agent is an antibody or peptide, and step (a) occurs before step (b). In some embodiments, the active agent is a small molecule, and step (a) occurs after step (b).

[0161] The nanoparticles, first polymer linkers, second polymer linkers, brain internalization transporter moieties, and active agents suitable for use in the preparation process are those described above in connection with various aspects and embodiments of the nanodelivery system.

[0162] Pharmaceutical Composition In yet another aspect, a pharmaceutical composition is provided comprising a nanodelivery system according to various embodiments described above and a pharmaceutically acceptable carrier.

[0163] As used herein, a "pharmaceutically acceptable formulation," "pharmaceutical composition," or "pharmaceutically acceptable composition" may contain any of a number of carriers known to those skilled in the art, such as solvents, dispersion media, coatings, surfactants, antioxidants, preservatives (e.g., antibacterial agents, antifungal agents), isotonicity agents, absorption delaying agents, salts, preservatives, drugs, drug stabilizers, gels, binders, excipients, disintegrants, lubricants, sweeteners, flavorings, dyes, such materials, and combinations thereof (Remington's, 1990). Pharmaceutical compositions containing the nanoparticles of the present disclosure as active ingredients can be prepared according to conventional pharmaceutical compounding techniques. See, for example, Remington's Pharmaceutical Sciences, 18th Ed., Mack Publishing Co., Easton, Pa. (1990). See also Remington: The Science and Practice of Pharmacy, 21st Ed., Lippincott Williams & Wilkins, Philadelphia, Pa. (2005).

[0164] The composition may contain different types of carriers depending on whether it is administered in solid, liquid or aerosol form, and whether it needs to be sterile for administration route such as injection.Those skilled in the art will be familiar with the techniques for making sterile solutions for application by injection or any other route.Sterile injection solutions are prepared by incorporating the active compound in the required amount into a suitable solvent with various other ingredients well known to those skilled in the art.

[0165] The carriers may, in total, constitute from about 0.1% to about 99.99999% by weight of the pharmaceutical compositions provided herein.

[0166] According to some embodiments, the pharmaceutical composition is formulated for systemic administration. According to some embodiments, the pharmaceutical composition is formulated for systemic administration selected from intravenous and intranasal administration. According to some embodiments, the pharmaceutical composition is formulated for intravenous administration. According to some embodiments, the pharmaceutical composition is formulated for intranasal administration. According to some embodiments, the pharmaceutical composition is formulated for intrathecal administration.

[0167] Compositions contemplated herein may take the form of a solution, suspension, emulsion, aerosol, combinations thereof, or any other pharmaceutically acceptable composition as generally known in the art.

[0168] In some embodiments, the carrier is a solvent. As a non-limiting example, the composition may be placed in a solvent. Such solvents include any suitable solvent known in the art, such as water, saline, phosphate buffered saline, etc.

[0169] The formulation of the composition may vary depending on the route of administration. For parenteral administration in an aqueous solution, for example, the solution should be suitably buffered if necessary and the liquid diluent should first be rendered isotonic with sufficient saline or glucose. Sterile aqueous vehicles that can be used will be known to those skilled in the art in light of the present disclosure.

[0170] Supplementary active ingredients can also be incorporated into the composition.For human administration, preparations should meet the sterility and general safety and purity standards as required by the FDA Division of Biologics.Administration can be by any known route.

[0171] In certain embodiments, the pharmaceutical composition comprises at least about 0.001 g to about 1 g of particles disclosed herein per kilogram of subject.

[0172] Pharmaceutical compositions may contain various antioxidants to retard oxidation of one or more components. Additionally, prevention of microbial action can be achieved by preservatives such as various antibacterial and antifungal agents, including, but not limited to, parabens (e.g., methylparaben, propylparaben), chlorobutanol, phenol, sorbic acid, thimerosal, or combinations thereof. The compositions must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms such as bacteria and fungi. It will be appreciated that exotoxin contamination should be kept to a minimum, for example, at a safe level of less than 0.5 ng / mg protein.

[0173] In embodiments in which the composition is in liquid form, the carrier can be a solvent or dispersion medium, including, but not limited to, water, ethanol, polyols (e.g., glycerin, propylene glycol, liquid polyethylene glycol, etc.), lipids (e.g., triglycerides, vegetable oils, liposomes), and combinations thereof. In many cases, it will be preferable to include isotonic agents, such as, for example, sugars, sodium chloride, or combinations thereof.

[0174] In other embodiments, nasal solutions or sprays, aerosols or inhalants may be used. Nasal solutions are usually aqueous solutions designed to be administered to the nasal passages in drops or sprays.

[0175] Solid compositions for oral administration are also contemplated, hi these embodiments, the solid compositions may comprise, for example, solutions, suspensions, emulsions, tablets, pills, capsules, sustained release formulations, buccal tablet compositions, troches, elixirs, suspensions, syrups, or combinations thereof.

[0176] Sterile injectable solutions are prepared by incorporating the active compound (e.g., nanoparticles) in the required amount in an appropriate solvent along with various other ingredients listed above. The liquid medium should be suitably buffered if necessary, and the liquid diluent should first be rendered isotonic with sufficient saline or glucose prior to injection.

[0177] Dosage is repeated as needed as determined by those skilled in the art.Therefore, in some embodiments of the method described herein, single dose is contemplated.In other embodiments, two or more doses are contemplated.When two or more doses are administered to the subject, the time interval between administrations can be any time interval as determined by those skilled in the art.

[0178] Therapeutic and Diagnostic Uses of the Compositions According to some embodiments, the pharmaceutical composition is for the prevention of a disease in a subject in need thereof. According to some embodiments, the pharmaceutical composition is for the treatment of a disease in a subject in need thereof. According to some embodiments, the pharmaceutical composition is for the monitoring of a disease in a subject in need thereof. In some embodiments, the disease is a brain-related disease or disorder.

[0179] In some embodiments, the disease is a central nervous system disease. According to some embodiments, the disease or disorder is a brain disorder.

[0180] In some embodiments, the pharmaceutical composition is for the treatment of a brain-related disease or disorder, in some embodiments, the brain-related disease or disorder is selected from the group consisting of brain-related cancer, neurodegenerative disorder, neuromuscular disease, neurodevelopmental disease, autoimmune brain-related disease, neuropsychiatric disorder, seizure disorder, pain disorder, cerebrovascular disorder, neurodevelopmental disease, and neuroinfectious disease.

[0181] In some embodiments, the brain-related disease is a brain-related cancer. As used herein, the term "brain-related cancer" encompasses both primary and metastatic brain tumors. In some embodiments, the brain-related cancer is selected from the group consisting of, but not limited to, brain and neural tumors, brain metastases, glioma, glioblastoma (GBM), and gliosarcoma (GS). In some embodiments, the brain-related disease is a neurodegenerative disorder. In some embodiments, the neurodegenerative disorder is selected from the group consisting of Parkinson's disease, Alzheimer's disease, Huntington's disease, and dementia. In some embodiments, the brain-related disease is a neuromuscular disease. In some embodiments, the neuromuscular disease is selected from the group consisting of amyotrophic lateral sclerosis (ALS) and motor neuron disease. In some embodiments, the brain-related disease is a neurodevelopmental disease. In some embodiments, the neurodevelopmental disease is selected from the group consisting of autism spectrum disorder and attention deficit hyperactivity disorder (ADHD). In some embodiments, the brain-related disease is multiple sclerosis (MS). In some embodiments, the brain-related disease is a neuropsychiatric disorder. In some embodiments, the neuropsychiatric disorder is selected from the group consisting of schizophrenia, drug addiction, smoking addiction, eating disorders, obsessive-compulsive disorder, various forms of depression, anxiety disorders, cognitive disorders, and affective disorders. In some embodiments, the brain-related disease is a seizure disorder. In some embodiments, the seizure disorder is epilepsy. In some embodiments, the brain-related disease is a pain disorder. In some embodiments, the brain-related disease is a cerebrovascular disorder. In some embodiments, the cerebrovascular disorder is selected from traumatic brain injury and stroke. In some embodiments, the brain-related disease is a neurodevelopmental disease. In some embodiments, the neurodevelopmental disease is selected from the group consisting of Huntington's disease, Kennedy's disease, metabolic disorders, lysosomal storage diseases, and Duchenne's disease. In some embodiments, the brain-related disease is a neuroinfectious disease.

[0182] In some embodiments, the brain-related disease is Alzheimer's disease. In some embodiments, the brain-related disease is Parkinson's disease. According to some embodiments, the brain-related disease is Huntington's disease, spinocerebellar ataxia, amyotrophic lateral sclerosis, Friedreich's ataxia, motor neuron disease (Lou Gehrig's disease), or spinal muscular atrophy. According to some embodiments, the brain-related disease is a prion disease.

[0183] As used herein, the term "subject" refers to any animal (e.g., mammal) (e.g., that will be the recipient of a particular treatment), including, but not limited to, humans, non-human primates, rodents, etc. Typically, the terms "subject" and "patient" are used interchangeably unless otherwise indicated herein.

[0184] In some embodiments, the subject is a human subject. In some embodiments, the subject is at risk for suffering from a brain-related disease, disorder, or medical condition. In some embodiments, the subject has been diagnosed with a brain-related disease, disorder, or medical condition. In some embodiments, the subject has been diagnosed with a brain-related genetic disorder. In some embodiments, the subject is at risk for suffering from a neurodegenerative disease. In some embodiments, the subject has been diagnosed with a neurodegenerative disease. In some embodiments, the subject has been diagnosed with Alzheimer's disease. In some embodiments, the subject has been diagnosed with Parkinson's disease.

[0185] As used herein, a subject at risk of suffering from a disease, disorder, or medical condition is a subject who exhibits one or more signs or symptoms indicating a disease, disorder, or medical condition, or is examined for a disease, disorder, or medical condition (e.g., during a routine checkup).A subject at risk of suffering from a disease, disorder, or medical condition may also have one or more risk factors.A subject at risk of suffering from a disease, disorder, or medical condition includes individuals who have not previously been examined for the disease, disorder, or medical condition.However, a subject at risk of suffering from a disease, disorder, or medical condition also includes individuals who have received a preliminary diagnosis but have not undergone a confirmatory test (e.g., biopsy and / or histological examination), or whose stage of the disease, disorder, or medical condition is unknown.The term also includes people who have previously suffered from the disease, disorder, or medical condition (e.g., individuals who are in remission).

[0186] A subject at risk for suffering from a brain-related disease, disorder, or medical condition may be diagnosed with the brain-related disease, disorder, or medical condition, or alternatively may be found to be free of the brain-related disease, disorder, or medical condition.

[0187] As used herein, a patient diagnosed with a brain-related disease, disorder, or medical condition can be diagnosed using any suitable method, including, but not limited to, biopsy, X-ray, blood test, and the diagnostic method of the present invention. A "preliminary diagnosis" is based solely on visual examination (e.g., CT scan or the presence of a mass) and antigen testing.

[0188] In some embodiments, the subject is suffering from a brain-related disease, disorder, or medical condition, and the imaging method is used to determine the stage of the disease, disorder, or medical condition. In some embodiments, the subject suffering from a brain-related disease, disorder, or medical condition is being treated with a drug, and the imaging method is used to follow up the treatment.

[0189] As used herein, the terms "treatment," "treating," or "amelioration" of a disease, disorder, or condition refers to the alleviation of at least one symptom thereof, the reduction in its severity, or the inhibition of its progression. Treatment does not necessarily mean that the disease, disorder, or condition is completely cured. To be an effective treatment, a useful composition herein need only reduce the severity of the disease, disorder, or condition, reduce the severity of symptoms associated therewith, or provide an improvement in the quality of life of the patient or subject.

[0190] In some embodiments, the present invention provides a method of administering an active agent for the prevention, treatment, and / or monitoring of a brain-related disorder in a subject in need thereof, the method comprising administering to the subject a pharmaceutical composition comprising a nanodelivery system of the present invention in all its embodiments. According to some currently preferred embodiments, the method comprises delivering the active agent to a brain region of the subject.

[0191] In some embodiments, the method further comprises imaging the brain region of the subject, thereby assessing accumulation of the nanodelivery system in the brain of said subject. In some embodiments, the imaging is performed using an imaging system selected from the group consisting of computed tomography (CT), X-ray imaging, magnetic resonance imaging (MRI), positron emission tomography (PET), single photon emission computed tomography (SPECT), ultrasound (US), and any combination thereof.

[0192] In some embodiments, the present invention provides a theranostic method, comprising administering a pharmaceutical composition of the present invention to a subject in need thereof and imaging a target site in the subject to determine whether the nanoparticles have accumulated at the target site in the subject. In some embodiments, the target site is a site in the brain of the subject.

[0193] In some embodiments, administering the composition to a subject can be performed using any method known to those skilled in the art. The mode of administration can vary based on the application. For example, the mode of administration can vary depending on the specific cell, brain region, or subject to be imaged. For example, the composition can be administered intravenously, intracerebrally, intracranially, intrathecally, intraventricularly, intrasubstantia nigra or substantia nigra region, intradermally, intraarterially, intraperitoneally, intralesionally, intratracheally, intranasally, intramuscularly, intraperitoneally, subcutaneously, orally, topically, locally, by inhalation (e.g., aerosol inhalation), by injection, by infusion, by intrathecal injection, by transmucosal injection, by intracarotid injection, by continuous infusion, by local perfusion directly bathing the target cells, via a catheter, by lavage, or by any other method known to those skilled in the art, or by any combination of the foregoing.

[0194] In some embodiments, the pharmaceutical composition is administered to a subject by a systemic route. In some embodiments, the systemic administration is selected from intravenous (IV) administration and intranasal (IN) administration. In some embodiments, the pharmaceutical composition is administered to a subject by intrathecal (IT) administration.

[0195] In some embodiments, the particles are administered intravenously. In some embodiments, the particles are administered intranasally.

[0196] Upon formulation, compositions will be administered in a manner compatible with the dosage formulation, and in such amount as is effective, For example, nanoparticles can be administered in such amount as is effective for the particular imaging application desired.

[0197] The effective amount of the pharmaceutical composition is determined based on the intended purpose, for example, based on the imaging method and the subject or part of the subject to be imaged. The amount administered may also vary based on the specific administration route used. The composition is preferably administered in a "safe and effective amount." As used herein, the term "safe and effective amount" refers to an amount of the composition that is sufficient for the intended purpose (e.g., imaging) without causing excessive adverse side effects (such as toxicity, irritation, or allergic reaction).

[0198] In some embodiments, imaging of the target site is performed by an imaging technique that utilizes penetrating radiation. According to some embodiments, the imaging technique is selected from the group consisting of magnetic resonance imaging (MRI), computed tomography (CT), X-ray imaging, positron emission tomography (PET), single photon emission computed tomography (SPECT), and ultrasound (US).

[0199] In some embodiments, the imaging step is performed 0.5 to 96 hours after the administering step. In some embodiments, the imaging step is performed 0.5 to 48 hours after the administering step. In some embodiments, the imaging step is performed 0.5 to 24 hours after the administering step. In some embodiments, the imaging step is performed 0.5 to 12 hours after the administering step. In some embodiments, the imaging step is performed 1 to 12 hours after the administering step. In some embodiments, the imaging step is performed 1 to 6 hours after the administering step. In some embodiments, the imaging step is performed within 96 hours of the administering step. In some embodiments, the imaging step is performed within 48 hours of the administering step. In some embodiments, the imaging step is performed within 24 hours of the administering step. In some embodiments, the imaging step is performed within 12 hours of the administering step. In some embodiments, the imaging step is performed within 6 hours of the administering step.

[0200] In some embodiments, the method includes determining whether the nanoparticles have accumulated at the target site in the subject. In some embodiments, the treatment decision may be to not administer treatment. In some embodiments, the analysis of the imaging data is used to determine an appropriate treatment route for the patient. In some embodiments, the determination of an appropriate treatment route for the patient depends, for example, on the stage of the disease, disorder, or medical condition and the patient's health status. In some embodiments, the treatment route includes one or more protocols of treatment selected from the group including intravenous, intranasal, intraperitoneal, intramuscular, and subcutaneous, and any other biological or inorganic product for treatment. In some embodiments, the treatment is administered after imaging. In some embodiments, the treatment is administered to the subject in real time while the subject is being imaged.

[0201] In some embodiments, imaging and treating the subject are performed simultaneously, hi some embodiments, bioactive molecules can be activated at the target site in the subject after imaging.

[0202] kit In some embodiments, the present invention provides kits comprising one or more compositions disclosed herein. In some embodiments, the present invention provides kits useful for the methods disclosed herein. For example, the kit may include a container having a sterile reservoir containing any of the compositions disclosed herein. In some embodiments, the kit further includes instructions. For example, the kit may include instructions (e.g., indications, dosage, method, etc.) for administering the composition to a subject. In yet another example, the kit may include instructions for applying the compositions and methods of the present invention to an imaging system, such as computed tomography (CT), ultrasound (US), or magnetic resonance imaging (MRI).

[0203] The description of various embodiments of the present invention has been presented for purposes of illustration and is not intended to be exhaustive or to be limited to the disclosed embodiments. Many modifications and variations will be apparent to those skilled in the art without departing from the scope and spirit of the described embodiments. The terms used herein have been selected to best explain the principles of the embodiments, practical applications, or technical improvements over commercially available technologies, or to enable those skilled in the art to understand the embodiments disclosed herein.

[0204] Any concentration range, percentage range, or ratio range recited herein should be understood to include concentrations, percentages, or ratios of any integer within that range, and fractions thereof, such as tenths and hundredths of the integer, unless otherwise indicated.

[0205] Any numerical range recited herein with respect to any physical characteristic, such as polymer subunits, size, or thickness, should be understood to include any integer within the recited range, unless otherwise indicated.

[0206] As used herein, the term "about" when combined with a value refers to ±10% of the reference value. For example, a molecular weight of about 1000 Da refers to a molecular weight of 1000 Da ±100 Da.

[0207] It should be noted that, as used in this specification and the appended claims, the singular forms "a," "an," and "the" include plural referents unless the context clearly dictates otherwise. Thus, for example, a reference to "a polynucleotide" includes a plurality of such polynucleotides; a reference to "the polypeptide" includes a reference to one or more polynucleotides and equivalents thereof known to those skilled in the art; and so on. This statement, therefore, is intended to serve as a predicate for use of exclusive terminology, such as "sole," "only," and the like, in connection with the recitation of claim elements or the use of a "negative" limitation.

[0208] The term "plurality" means "two or more" unless expressly specified otherwise.

[0209] When a conventional expression similar to "at least one of A, B, and C, etc." is used, such syntax is generally intended in the sense that one of ordinary skill in the art would understand the conventional expression (e.g., "a system having at least one of A, B, and C" includes, but is not limited to, systems having A only, B only, C only, A and B, A and C, B and C, and / or A, B, and C, etc.). It will be further understood by those skilled in the art that most disjunctive words and / or phrases indicating two or more alternative terms, whether in the specification, claims, or drawings, should be understood to contemplate the possibility of including one of the terms, either one of the terms, or both terms. For example, the phrase "A or B" is understood to include the possibilities of "A" or "B" or "A and B."

[0210] It is understood that certain features of the invention, which are, for clarity, described in the context of separate embodiments, may also be provided in combination in a single embodiment. Conversely, various features of the invention, which are, for brevity, described in the context of a single embodiment, may also be provided separately or in any suitable subcombination. All combinations of the embodiments belonging to the invention are specifically embraced by the invention and are disclosed herein just as if each and every combination were individually and explicitly disclosed. In addition, all subcombinations of the various embodiments and elements thereof are also specifically embraced by the invention and are disclosed herein just as if each and every such subcombination were individually and explicitly disclosed herein.

[0211] Additional objects, advantages, and novel features of the present invention will become apparent to those skilled in the art upon examination of the following examples, which are not intended to be limiting. Additionally, each of the various embodiments and aspects of the present invention as described above and as claimed in the claims section below finds experimental support in the following examples.

[0212] Various embodiments and aspects of the present invention as delineated hereinabove and as claimed in the claims section below find experimental support in the following examples.

[0213] Example Generally, the terminology used herein and the laboratory techniques utilized in the present invention include molecular, biochemical, microbiological, and recombinant DNA techniques. Such techniques are fully explained in the literature. See, for example, "Molecular Cloning: A Laboratory Manual" by Sambrook et al. (1989); "Current Protocols in Molecular Biology" Volumes I-III, Ausubel, R.M., ed. (1994); Ausubel et al., "Current Protocols in Molecular Biology," John Wiley & Sons, Baltimore, Maryland (1989); Perbal, "A Practical Guide to Molecular Cloning," John Wiley & Sons, New York (1988); Watson et al., "Recombinant DNA," Scientific American Books, New York; and Birren et al. (eds.) "Genome Analysis: A Laboratory Manual Series," Vols. 1-4, Cold Spring Harbor Laboratory Press, New York, all of which are incorporated by reference. (1998); methodologies such as those described in U.S. Patent Nos. 4,666,828; 4,683,202; 4,801,531; 5,192,659 and 5,272,057; "Cell Biology: A Laboratory Handbook", Volumes I-III Cellis, JE, ed. (1994); "Culture of Animal Cells - A Manual of Basic Technique" by Freshney, Wiley-Liss, NY (1994), Third Edition; "Current Protocols in Immunology" Volumes I-III Coligan JE, ed.(1994); Stites et al. (eds), "Basic and Clinical Immunology" (8th Edition), Appleton & Lange, Norwalk, CT (1994); Mishell and Shiigi (eds), "Strategies for Protein Purification and Characterization - A Laboratory Course Manual" CSHL Press (1996). Other general references are provided throughout this specification.

[0214] Example 1: Preparation and characterization of insulin and EGFR antibody coated gold nanoparticles (GNPs) (EGFR&Ins-GNPs) FIG. 1 shows a schematic diagram of a non-limiting exemplary particle, depicting a gold nanoparticle (GNP) coated with a polymer layer comprising a first polymer linker (e.g., -S-PEG-C(O)-, ∼5 kDa) conjugated to insulin, a second polymer linker (e.g., -S-PEG-C(O)-, ∼3.5 kDa) conjugated to a bioactive molecule (e.g., an antibody), and a third monofunctional polymer moiety (e.g., -S-PEG-O-CH3, ∼5 kDa).

[0215] GNP synthesis 20 nm spherical GNPs were prepared by citrate reduction of HAuCl4. A total of 414 μl of 50% w / v HAuCl4 solution in 200 ml of distilled water was brought to a boil in a water bath on a heating plate while stirring. After boiling, 4.04 ml of 10% sodium citrate solution was added, and the mixture was stirred for an additional 10 minutes while boiling. After removing the solution from the plate and cooling to room temperature, the solution was centrifuged until the nanoparticles precipitated.

[0216] Conjugation of PEG5000 and insulin to GNPs GNPs were first partially coated (85% of the particle surface) with mPEG-SH (~5 kDa; 70% of the particle surface) and heterofunctional HS-PEG-COOH (~5 kDa; 15% of the particle surface). The amounts of mPEG-SH and HS-PEG-COOH required for partial coating were determined by the thiol-PEG molecules, which were 0.35 nm thick on the gold nanoparticle surface. 2 This was derived from theoretical calculations based on the finding that the HS-PEG-COOH (145 μl, 50 mg / ml) and mPEG-SH (677 μl, 50 mg / ml) mixture was added to the GNP solution and mixed for 2 hours. The solution was then ultracentrifuged at 15,000 RPM for 20 minutes and then again at 20,000 RPM for 15 minutes. The precipitate, containing PEG-coated GNPs (85% total coating), was transferred to a vial. Insulin was then covalently conjugated to the carboxyl groups of HS-PEG-COOH by adding an excess amount of insulin together with EDC (1-ethyl-3-(3-dimethylaminopropyl)carbodiimide HCl) and NHS (N-hydroxysulfosuccinimide sodium salt) on ice, followed by mixing for 2 hours. The solution was then centrifuged at 14,000 RPM for 30 minutes (kept cold) and the lower phase containing Ins-PEG-GNPs was transferred to a vial.

[0217] Conjugation of PEG3500 and EGFR Ab to GNPs To further conjugate EGFR Ab to the GNPs, 102 μl of HS-PEG-COOH (∼3.5 kDa) solution (50 mg / ml) was added to the partially coated GNPs to coat the remaining 15% of the particle surface. The solution was then mixed at 4°C for 2 hours, followed by centrifugation at 14,000 RPM for 30 minutes. EGFR Ab was then covalently conjugated to the free carboxyl groups of HS-PEG-COOH (∼3.5 kDa) by adding an excess amount of EGFR Ab along with EDC and NHS. The solution was then stirred at 4°C for 2 hours, followed by centrifugation to reach a final Au concentration of 30 mg / ml.

[0218] EGFR&Ins-GNPs were characterized using UV-Vis spectroscopy after each step of preparation (Figure 2). The shift in UV-Vis signal after different coating levels confirmed the success of the coating.

[0219] The covalent conjugation between the PEG linker and insulin and EGFR Ab was confirmed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). Free insulin, free EGFR Ab, GNPs, PEG-coated GNPs (GNPs + PEG), insulin-coated GNPs (GNPs + PEG + INS), and EGFR & Ins-GNPs (GNPs + PEG + INS + Ab) were analyzed by SDS-PAGE (run at 120 V for 60 min). As seen in Figure 3, neither insulin nor EGFR Ab separated from the GNPs during the electrophoresis process, indicating stable covalent conjugation.

[0220] Example 2: Delivery of EGFR&Ins-GNPs into the brain of mice Thirteen male BALB / c mice, each weighing 20-25 g, were divided into three groups. The first group (control; n = 3) received IV administration of control GNPs (200 μl; 30 mg / ml). Control GNPs were prepared by coating 20 nm spherical GNPs with a 5 kDa layer of mPEG-SH (mPEG-GNPs). The second group (n = 5) received intravenous administration of 200 μl of 30 mg / ml EGFR-Ins-GNPs via the tail vein. The third group (n = 5) received intranasal administration of 20 μl of EGFR-Ins-GNPs. All mice were anesthetized and sacrificed 5 hours after administration. The mice underwent perfusion to remove any particles present in the blood vessels.

[0221] After sacrifice, the brains of the mice were scanned by a micro-CT scanner. As seen in Figure 4A, no accumulation of GNPs was observed in the brains of control mice that received non-targeted mPEG-GNPs. In contrast, micro-CT images of the brains of mice from the second and third groups (Figures 4B and 4C, respectively) show clearly visible accumulation of EGFR&Ins-GNPs.

[0222] The accumulation of GNPs in the mouse brain was further quantitatively measured by ICP-MS analysis of mouse brain samples, showing a total amount of 13.45 μg Au (approximately 1.6646E+14 particles according to theoretical calculations) in the brain after intravenous administration and 0.42 μg Au (approximately 5.19772E+12 particles according to theoretical calculations) in the brain after intranasal administration.

[0223] Overall, the results indicate that insulin ligands promote the transport of GNP complexes across the BBB, resulting in significant penetration of EGFR&Ins-GNPs into the brain after either intravenous or intranasal administration, with a greater amount of particles penetrating into the brain after IV administration. However, microCT images showed that the particles reached different sites when administered via the IV or IN route. Therefore, the results further suggest that EGFR&Ins-GNPs may serve as a CT contrast agent to label specific brain regions where they accumulate.

[0224] Example 3: Biodistribution and pharmacokinetic profile of EGFR&Ins-GNPs To investigate the amount of EGFR&Ins-GNP in the brain and its distribution throughout the body, EGFR&Ins-GNP was intravenously injected into the tail vein of male BALB / c mice. The mice were sacrificed at various time points up to 1 month after injection (n=3 per time point), and their brains, kidneys, and livers were collected for ICP-MS analysis to quantify the amount of gold in the organs over time.

[0225] As demonstrated in Figure 5A, EGFR&Ins-GNPs rapidly accumulated in the brain and remained at high concentrations for up to 5 hours after injection. Gradual excretion of the particles from the brain was then observed, with only small amounts of gold remaining 1 week after injection and complete excretion 1 month after injection.

[0226] In addition, as seen in Figure 5B, EGFR&Ins-GNPs accumulated in the kidney and liver up to 24 hours after injection and were then excreted from these organs up to 1 month after injection.

[0227] Example 4: Delivery of IgG1&Ins-GNPs into the brain of mice Fluorescent antibody IgG1 (mouse monoclonal IgG1 Alexa Fluor 488 isotype, clone 11711) and insulin-coated GNPs (IgG1&Ins-GNPs) were synthesized as described in Example 1 with the following differences: 1) A fluorescent IgG1 antibody was used instead of EGFR Ab. 2) HS-PEG-COOH (~5 kDa): 193 μl was added instead of 145 μl (~20% of the particle surface). 3) mPEG-SH (~5 kDa): 580 μl was added instead of 677 μl (~60% of the particle surface). 4) HS-PEG-COOH (~3.5 kDa): 136 μl was added instead of 102 μl (~20% of the particle surface).

[0228] Mice were injected IV with either 200 μl of 30 mg / ml IgG1&Ins-GNP (n=5) or an equivalent amount (0.4 mg) of free fluorescent IgG1 antibody (n=3). Eight hours after injection, mouse brains were extracted and analyzed using ICP-MS (n=3) or immunohistochemistry (n=2).

[0229] As demonstrated in Figure 6A, quantitative ICP-MS analysis indicated successful penetration of IgG1&Ins-GNPs into the brain (Figure 6A).

[0230] The fixation and permeabilization method (FPM) used for immunohistochemistry fluorescence (IHC F) was FPM13, and sections were collected from the cerebral cortex. 7-μm brain frozen sections were prepared using a cryostat and immunostained. 4',6-diamidino-2-phenylindole (DAPI) was used for nuclear DNA labeling. Fluorescent antibody signals were detected and photographed using a confocal microscope. All photographs were taken under the same exposure conditions. As seen in Figure 6B, strong fluorescence was observed in the brain sections of mice treated with IgG1&Ins-GNPs (right panel), whereas no fluorescence was observed except for the DAPI signal in the brain sections of mice treated with free fluorescent antibody (left panel). These results indicate that the targeted GNP system facilitates brain penetration of antibodies that naturally have limited ability to transport across the BBB.

[0231] Example 5: Delivery of anti-Iba1&Ins-GNPs into the brain of mice GNPs coated with insulin and anti-Iba1 fluorescent antibody (antibody of microglial cells) were synthesized as described in Example 4, using fluorescent anti-Iba1 (rabbit monoclonal - Alexa fluor 647) instead of IgG1 Ab.

[0232] Mice were intravenously injected with either 200 μl of 30 mg / ml anti-Iba1&Ins-GNP or an equivalent amount (0.1 mg) of free fluorescent anti-Iba1. Seven hours after injection, mice were sacrificed and perfused. Mouse brains were then sectioned and imaged using super-resolution microscopy. Vascular muscles were stained with Alexa Fluor 568, and BBB endothelial cells were stained with CD31-Alexa Fluor 488.

[0233] As seen in Figures 7A and 7B, super-resolution microscopy images showed the migration of anti-Iba1&Ins-GNPs into the brain (Figure 7A), while free antibody was blocked within cerebral blood vessels (Figure 7B).

[0234] Example 6: Functionality of antibodies after covalent conjugation to GNP shuttles To confirm that antibodies remain functional when conjugated to the GNP shuttle, in vitro experiments were performed using the anti-TGF-β antibody fresolimumab. Binding of fresolimumab to the TGF-β cytokine secreted by cancer cells enhances immune system activity, as indicated by elevated tumor necrosis factor (TNF)-α.

[0235] Fresolimumab & Ins-GNP was synthesized as described in Example 1, substituting fresolimumab for EGFR Ab.

[0236] One microliter of fresolimumab and Ins-GNPs was added to co-cultures of Skmel23 cancer cells and F4-T cells containing soluble TGF-β. After overnight incubation, TNF-α secretion was quantified using an ELISA and compared with that of control cells without fresolimumab and Ins-GNPs.

[0237] Interestingly, higher concentrations of TNF-α were observed in cells treated with fresolimumab & Ins-GNPs compared to untreated cells, indicating that the antibody retains its activity despite being anchored to the GNP complex by covalent conjugation to the PEG linker.

[0238] Example 7: Delivery of peptides & Ins-GNPs into the brain To investigate the ability of the nanoplatform to deliver peptides into the brain, we used a cyclic peptide (with the structure shown below) that targets amyloid-β (Aβ) plaques present in the brains of Alzheimer's disease patients. [ka]

[0239] Cyclic peptide (PEP) was conjugated to Ins-GNP to form PEP&Ins-GNP. The synthesis process was carried out as described in Example 1, using cyclic D,L-α-peptide instead of EGFR Ab.

[0240] The particles were characterized after the different conjugation steps using UV-Vis spectroscopy (Figure 8), dynamic light scattering (DLS), and zeta potential measurements. Table 1 shows the zeta potential and hydrodynamic diameter of bare GNPs, GNPs + PEG (after the first conjugation step), and the final particles coated with insulin and peptides. [Table 1]

[0241] After coating the particles, a decrease in zeta potential value to a near-neutral level and an increase in particle diameter confirmed the chemical coating. Additionally, broadening and shifts in the UV-visible signal were observed for different coating levels (Figure 8).

[0242] For in vivo experiments, the 5XFAD mouse model of Alzheimer's disease (AD, 4 months old) was used.

[0243] PEP&Ins-GNPs were intravenously injected (200 μl, 25 mg / ml) into the tail vein of 5xFAD mice (n=5) and WT mice (n=5). Six hours after IV injection, the mice were sacrificed, perfused, and scanned using a micro-CT scanner (Figures 9A and 9B). After IV administration, PEP&Ins-GNPs penetrated into the brains of both healthy and diseased mice, and were significantly more accumulated in the diseased brains (Figure 9B) than in the healthy brains (Figure 9A).

[0244] The accumulation of PEP&Ins-GNPs in the brains of mice was further quantitatively measured by ICP-MS analysis of mouse brain samples (Figure 9C). The results showed that the accumulation of PEP&Ins-GNPs in the brains of AD mice was four times higher than that in healthy brains, indicating that these particles are gradually excreted from healthy brains but are retained for a longer period in the brains of AD mice due to the conjugated peptides targeting Aβ plaques.

[0245] To further investigate the targeting ability of the cyclic peptide, fluorescently labeled PEP&Ins-GNPs were synthesized using the rhodamine B-labeled peptide. The fluorescently labeled PEP&Ins-GNPs were incubated with unfixed coronal sections of hippocampus from WT or h5xFAD mice at 4°C for 20 hours. The sections were then co-stained with anti-Aβ antibody 6E10 to identify Aβ plaques and DAPI to stain cell nuclei. Brain sections from AD mice showed distinct staining of PEP&Ins-GNPs co-localized with the staining of Aβ plaques (Figure 9D), indicating that the peptide retains its functionality and targeting ability despite being conjugated to a GNP carrier.

[0246] Example 8: Delivery of CisPt-Ins-GNPs into the mouse brain The ability of the GNP platform to deliver bioactive small molecules into the brain was examined with cisplatin (CisPt), a chemotherapeutic agent with poor BBB penetration.

[0247] Synthesis of cisplatin + insulin-GNPs 20 nm spherical GNPs (synthesized as described in Example 1) were first partially coated (80% of the particle surface) with mPEG-SH (5 kDa; 60% of the particle surface) and heterofunctional HS-PEG-COOH (1 kDa; 20% of the particle surface). Conjugation was performed by adding a mixture of HS-PEG-COOH (39 μl, 50 mg / ml) and mPEG-SH (580 μl, 50 mg / ml) to the GNP solution and mixing for 3 hours. The solution was then centrifuged at 14,000 g for 30 minutes. The precipitate containing the PEG-coated GNPs (80% coating) was transferred to a vial. Cisplatin was then covalently conjugated to the carboxyl groups of HS-PEG-COOH by adding an excess amount of cisplatin along with EDC and NHS, followed by mixing at 4 °C for 3 hours. The solution was then centrifuged at 14,000 g for 30 min at 4° C., and the lower phase containing cisplatin-GNPs was transferred to a vial.

[0248] To further conjugate insulin to the GNPs, HS-PEG-COOH (5 kDa) was added to the partially coated GNPs (194 μl, 50 mg / ml) to coat the remaining 20% ​​of the particle surface. The solution was then mixed at 4°C for 3 hours, followed by centrifugation at 14,000 g for 30 minutes at 4°C. Insulin was then covalently conjugated to the free carboxyl groups of HS-PEG-COOH (5 kDa) by adding an excess amount of insulin along with EDC and NHS. The solution was then stirred at 4°C for 3 hours, followed by centrifugation to reach a final Au concentration of 25 mg / ml.

[0249] In vivo experiments Six- to seven-week-old male BALB / c mice were intravenously administered 200 μl of cisplatin + insulin-GNP (approximately 0.1 mg of cisplatin according to ICP-MS measurement of Pt concentration) (n=3) or an equivalent dose of free cisplatin (100 μl, 1 mg / ml) (n=3) via the tail vein. Mice were sacrificed 8 hours after administration. Mice were perfused with 20 ml of saline to remove any particles present in the blood vessels.

[0250] After sacrifice and perfusion, the mouse brains were extracted and weighed, followed by ICP-MS analysis to quantify the amount of Au and Pt in the brain.

[0251] As seen in Figures 10A and 10B, both gold and platinum were found in the brains of mice administered cisplatin + insulin-GNPs, indicating successful delivery of GNPs to the brain. Furthermore, Figure 10B shows that the amount of Pt found in the brains of mice administered cisplatin + insulin-GNPs was significantly greater than that after administration of an equivalent dose of free cisplatin, indicating that the GNP platform enhances the penetration of the small molecule cisplatin through the BBB.

[0252] Further experiments were performed using similar GNPs coated with PJ34 as a small molecule drug (PJ34-Ins-GNPs) instead of insulin and cisplatin. Ex vivo microCT scanning of mouse brains 24 hours after intravenous administration of these particles demonstrated efficient penetration of PJ34-Ins-GNPs into the brain, providing further evidence for the feasibility of using the GNP platform to deliver small molecule therapeutics to the brain.

[0253] Example 9: Delivery of IgG1 & Ins coated iron oxide nanoparticles into the brain of mice Dextran-coated 50 nm spherical iron oxide nanoparticles (IONP) were purchased from Chemicell. The dextran coating was first removed from the particles by adding double-distilled water (DDW) and centrifuging at 12,000 RPM for 30 minutes.

[0254] The IONPs were then coated with insulin and IgG1 antibody via HS-PEG-COOH (~5 kDa) and HS-PEG-COOH (~3.5 kDa), respectively.

[0255] IONPs were first partially coated (85% of the particle surface) with mPEG-SH (~5 kDa; 70% of the particle surface) and heterofunctional HS-PEG-COOH (~5 kDa; 15% of the particle surface). The amounts of mPEG-SH and HS-PEG-COOH required for partial coating were derived from theoretical calculations based on the particle diameter and surface area. Conjugation was performed by adding a mixture of HS-PEG-COOH (58 μl, 50 mg / ml) and mPEG-SH (271 μl, 50 mg / ml) to the IONP solution and mixing for 2 hours. The solution was then centrifuged, and the precipitate containing the PEG-coated IONPs (85% total coating) was transferred to a vial. Insulin was then covalently conjugated to the carboxyl groups of HS-PEG-COOH by adding an excess amount of insulin along with EDC and NHS on ice, followed by mixing for 2 hours. The solution was then centrifuged, and the lower phase containing Ins-PEG-IONPs was transferred to a vial.

[0256] For the next coating step, HS-PEG-COOH (~3.5 kDa) was added (41 μl, 50 mg / ml) to the partially coated IONPs to coat the remaining 15% of the particle surface. The solution was then mixed for 2 hours at 4°C, followed by centrifugation. IgG1 was then covalently conjugated to the free carboxyl groups of HS-PEG-COOH (~3.5 kDa) by adding an excess amount of IgG1 along with EDC and NHS. The solution was then stirred for 2 hours at 4°C, followed by centrifugation to reach a final Fe concentration of 25 mg / ml.

[0257] In vivo experiments Male BALB / c mice (n=3) were intravenously injected with IgG1&Ins-IONP (200 μl; 25 mg / ml). After 8 hours, the mice were sacrificed and perfused to remove particles present in the blood vessels. The mouse brains were then extracted, and particle accumulation was assessed by quantitative measurement of Fe concentration using ICP-MS analysis.

[0258] The results showed that IgG1&Ins-IONPs efficiently penetrated into the brain, with an Fe concentration of 0.0047 mg Fe per gram of brain tissue 8 hours after injection. Therefore, it can be concluded that different nanoparticle types, specifically IONPs, can be used as the nanoparticle core in delivery systems.

[0259] Example 10: BBB permeability of GNPs coated with antibody (IgG1) and transferrin as the brain-internalizing moiety IgG1 and transferrin-coated GNPs (IgG1&Trf-GNPs) were synthesized as described in Example 1, using IgG1 antibody instead of EGFR Ab and human holotransferrin instead of insulin.

[0260] To investigate BBB permeability, in vitro BBB models were used. Human induced pluripotent stem cells (iPSCs) differentiated into BMEC-like cells (iBMECs) provide a robust source of human BBB models. iBMECs exhibit molecular, structural, and functional BBB characteristics, including transendothelial electrical resistance (TEER), that closely resemble the human cerebral vasculature. These BBB models use two-dimensional (2D) transwell inserts (Vatine, Gad D. et al., Cell Stem Cell 20.6 (2017): 831-843, and Lippmann, Ethan S. et al., Scientific Reports 4.1 (2014): 1-10).

[0261] 500,000 cells were cultured in a transwell, and the TEER value was approximately 3500 Ω×cm 2Cells were grown until they reached a concentration of 0.01%. TEER was measured, and then IgG1&Trf-GNPs, IgG1&Ins-GNPs, or mPEG-GNPs (control particles) were introduced into the upper medium (0.25 mg per million cells; n=2 per group). After 2 hours, TEER values ​​were measured again, and the decrease in TEER (compared to the initial value before adding particles) was calculated. A decrease in TEER value means lower resistance and indicates increased permeability through the tight layer of cells.

[0262] Figure 11 shows the decrease in TEER of the three groups. Both IgG1&Trf-GNPs (GNPs+IgG1+Trf) and IgG1&Ins-GNPs (GNPs+IgG1+Ins) were found to exhibit increased permeability through the tightly packed cell layer compared to control GNPs, indicating that the conjugated brain-internalizing moiety, i.e., insulin or transferrin, may enable these particles to penetrate into the brain in vivo. However, insulin-conjugated particles showed significantly enhanced permeability compared to transferrin-conjugated particles.

[0263] Example 11: Effect of insulin levels, antibody levels, and linker size on the ability of nanodelivery systems to cross the BBB To investigate the effect of linker size and the percent coverage of each coating molecule on the ability of the nanodelivery system to cross the BBB, various brain-targeted gold nanoparticles coated with insulin and IgG1 Ab were synthesized. Synthesis of all particles was carried out as described in Example 1, except for the MW of the PEG linkers used or their relative amounts (i.e., percent coverage). Table 2 specifies the different particles that were prepared and investigated. [Table 2] TIFF2025166069000005.tif94162

[0264] Brain-targeted particles listed in Table 1 were injected intravenously (200 μl of 30 mg / ml) into the tail vein of male BALB / c mice (n=2 per group). Eight hours after injection, the mice were sacrificed and perfused. The brains were then extracted and analyzed by ICP-MS to quantify the amount of gold that permeated through the BBB.

[0265] Figure 12A demonstrates the effect of insulin levels on the ability of particles to penetrate into the brain. It can be seen that coating GNPs with insulin at 5% or 10% coverage is not sufficient to deliver a significant amount of administered particles into the brain. However, coating particles with insulin at 15% or 20% coverage resulted in significant brain penetration. Surprisingly, GNPs coated with a higher concentration of insulin, i.e., 50%, showed significantly lower penetration into the brain. It is hypothesized that this result may be due to steric interference and structural constraints.

[0266] Figure 12B demonstrates the effect of antibody level within a nanodelivery system on its ability to penetrate into the brain. Among particles with different antibody levels, GNPs with a 20% antibody coating exhibited the highest brain penetration, while particles with higher antibody levels exhibited lower brain penetration. It should be noted, however, that although a 40% antibody coating resulted in lower GNP penetration compared to a 20% antibody coating, the total amount of antibody that penetrated into the brain using these particles was higher, due to the higher antibody concentration per particle.

[0267] Figure 12C demonstrates the effect of linker length on the ability of particles to penetrate into the brain. It can be seen that the highest brain penetration was achieved when PEG5000 and PEG3500 were used for insulin and Ab conjugation, respectively. Interestingly, when linkers with similar sizes were used for insulin and Ab conjugation (including relatively low and high MW linkers, i.e., PEG linkers with MW = 458 Da, 1000 kDa, and 3500 kDa), low brain penetration was obtained. Similarly, low brain penetration was obtained when PEG1000 and PEG3500 were used for insulin and Ab conjugation, respectively. These results suggest that to achieve efficient penetration into the brain through the BBB, insulin, which acts as a brain-internalizing moiety, should be exposed on the surface of the entire nanodelivery system (i.e., present on the outer surface of the particle shell). Insulin is much smaller than antibodies (5 kDa versus 150 kDa), and therefore must be conjugated to a longer linker than that used to attach it to the antibody in order to remain exposed on the surface of the nanodelivery system and not be blocked by the antibody.

[0268] Interestingly, when the antibody and insulin were conjugated to 5 kDa and 1 kDa PEG linkers, respectively, significant brain penetration was obtained (although this was lower than that obtained with Ins-PEG5000-Ab-PEG3500). Without wishing to be bound by theory or mechanism of action, this result may be explained by potential folding of the 5 kDa PEG linker, such that its effective length (i.e., end-to-end distance) is shorter, thereby allowing exposure of the insulin moiety.

[0269] While the present invention has been described in conjunction with specific embodiments thereof, it is evident that many alternatives, modifications, and variations will be apparent to those skilled in the art. Accordingly, it is intended to embrace all such alternatives, modifications, and variations that fall within the spirit and broad scope of the appended claims.

Claims

1. (a) an inorganic nanoparticle attached to a first linear polymer linker and a second linear polymer linker, wherein the first linear polymer linker and the second linear polymer linker have substantially different lengths; (b) a brain-internalizing transporter moiety conjugated to said first linear polymer linker; (c) an active agent selected from a biologically active molecule or a labeling molecule, wherein the active agent is conjugated to the second linear polymer linker; and A nano-delivery system comprising:

2. The nanodelivery system of claim 1 , wherein the first polymer linker and the second polymer linker are non-cleavable under physiological conditions.

3. 3. The nanodelivery system of claim 1, wherein the first linear polymer linker and the second linear polymer linker have a difference in their respective molecular weights of at least about 1000 Da.

4. The nanodelivery system of any one of claims 1 to 3, wherein the molecular weights of the first linear polymer linker and the second linear polymer linker are in the range of 1,000 to 10,000 Da.

5. The nanodelivery system of any one of claims 1 to 4, wherein the molecular weight of the first linear polymer linker is higher than the molecular weight of the second linear polymer linker.

6. The nanodelivery system of any one of claims 1 to 5, wherein the first linear polymer linker is composed of repeating monomer units, the second linear polymer linker is composed of the same repeating monomer units as the first linear polymer linker, and the first linear polymer linker has a different number of repeating monomer units than the second linear polymer linker.

7. 7. The nanodelivery system of claim 1, wherein the brain-internalizing transporter moiety is covalently conjugated to the first linear polymer linker via a first functional end group of the linker, and the active agent is covalently conjugated to the second linear polymer linker via a second functional end group of the linker.

8. The nanodelivery system of claim 7 , wherein the first functional end group and the second functional end group are the same.

9. 10. The nanodelivery system of claim 1, wherein the inorganic nanoparticles are attached to the second linear polymer linker via a sulfide bond and the active agent is conjugated to the second linear polymer linker via an amide bond.

10. The nanodelivery system of any one of claims 1 to 9, wherein the first linear polymer linker constitutes approximately 5% mol to 60% mol of the total polymer linkers attached to the inorganic nanoparticles.

11. The nanodelivery system of any one of claims 1 to 10, wherein the active agent is a biologically active molecule.

12. The nanodelivery system of any one of claims 1 to 11, wherein the active agent is selected from the group consisting of a polymer, a peptide, a small molecule, an oligonucleotide, an antisense RNA, and any combination thereof.

13. The nanodelivery system of claim 12 , wherein the polymer is an antibody.

14. The nanodelivery system of any one of claims 1 to 13, wherein the first linear polymer linker constitutes approximately 10% mol to 40% mol of the total polymer linkers attached to the inorganic nanoparticles.

15. The nanodelivery system of any one of claims 1 to 14, wherein the second linear polymer linker constitutes approximately 5% mol to 60% mol of the total polymer linkers attached to the inorganic nanoparticles.

16. 16. The nanodelivery system of any one of claims 1 to 15, wherein the first linear polymer linker and the second linear polymer linker independently comprise a polymer selected from the group consisting of polyethers, polyacrylates, polyanhydrides, polyvinyl alcohols, polysaccharides, poly(N-vinylpyrrolidone), polyglycerin (PG), poly(N-(2-hydroxypropyl)methacrylamide), polyoxazolines, poly(amino acid)-based hybrids, recombinant polypeptides, derivatives and combinations thereof.

17. 17. The nanodelivery system of claim 16, wherein at least one of the first linear polymer linker and the second linear polymer linker is a polyether.

18. 18. The nanodelivery system of claim 17, wherein the polyether is polyethylene glycol (PEG).

19. The polyethylene glycol (PEG) is thiolated PEG acid (HS-PEG-COOH) and thiolated PEG amine (HS-PEG-NH ２ 20. The nanodelivery system of claim 18, wherein the thiolated end is attached to the inorganic nanoparticle and the acid or amine end is conjugated to the brain-internalizing transporter moiety or the active agent.

20. The nanodelivery system of any one of claims 1 to 19, further comprising a third polymer linker attached to the inorganic nanoparticle, wherein the third polymer linker is monofunctional.

21. 21. The nanodelivery system of claim 20, wherein the third polymer linker comprises a polymer selected from the group consisting of polyethers, polyacrylates, polyanhydrides, polyvinyl alcohols, polysaccharides, poly(N-vinylpyrrolidone), polyglycerin (PG), poly(N-(2-hydroxypropyl)methacrylamide), polyoxazolines, poly(amino acid)-based hybrids, recombinant polypeptides, derivatives and combinations thereof.

22. 22. The nanodelivery system of claim 21, wherein the third polymer linker comprises a polyether, and the polyether is methoxypolyethylene glycol (mPEG).

23. The nanodelivery system of any one of claims 1 to 22, wherein the inorganic nanoparticles are selected from the group consisting of metal nanoparticles, metal oxide nanoparticles, ceramic nanoparticles, and any combination thereof.

24. 24. The nanodelivery system of claim 23, wherein the metal is selected from the group consisting of gold, silver, platinum, iron, and any combination thereof, and / or the metal oxide is selected from the group consisting of iron oxide, magnesium oxide, nickel oxide, cobalt oxide, aluminum oxide, zinc oxide, copper oxide, manganese oxide, and any combination thereof.

25. The nanodelivery system of any one of claims 1 to 24, wherein the inorganic nanoparticles are selected from the group consisting of gold, iron (III) oxide, and iron (II, III) oxide.

26. 26. The nanodelivery system of any one of claims 1 to 25, wherein the brain-internalizing transporter moiety is selected from the group consisting of insulin, an antibody specific for an insulin receptor, transferrin, an antibody specific for a transferrin receptor, a polypeptide that specifically binds to the transferrin receptor, a polypeptide that specifically binds to the insulin receptor, insulin-like growth factor 1, an antibody specific for insulin-like growth factor receptor 1, a polypeptide that specifically binds to insulin-like growth factor receptor 1, apolipoprotein A1, B, or E, lactoferrin, angiopep-2, low-density lipoprotein, an antibody specific for a low-density lipoprotein receptor or a lipoprotein receptor-related protein, a polypeptide that specifically binds to a low-density lipoprotein receptor or a lipoprotein receptor-related protein, an antibody specific for a diphtheria toxin receptor, a polypeptide that specifically binds to a diphtheria toxin receptor, a BBB-permeable cell-penetrating peptide (CPP), and any combination thereof.

27. 27. The nanodelivery system of claim 26, wherein the brain-internalizing transporter moiety is insulin.

28. The nanodelivery system of any one of claims 1 to 27, wherein the inorganic nanoparticles have a diameter of 10 to 160 nm.

29. A process for the preparation of the nanodelivery system of any one of claims 1 to 28, comprising the steps of: a) partially coating the surface of the inorganic nanoparticle with the first linear polymer linker, and then conjugating the first linear polymer linker to the brain-internalizing transporter moiety; b) partially coating the surface of the inorganic nanoparticles with the second linear polymer linker, and subsequently conjugating the second linear polymer linker to the active agent; Including, Steps (a) and (b) may be performed in any order. process.

30. 30. The process of claim 29, wherein the first polymer linker has a first functional end group configured to bind to the brain-internalizing transporter moiety and the second polymer linker has a second functional end group configured to bind to the active agent, and the first functional group and the second functional group are the same.

31. 31. The process of claim 29 or claim 30, further comprising partially coating the surface of the inorganic nanoparticles with a third polymer linker, wherein the polymer linker is a monofunctional linker.

32. 32. The process of any one of claims 29 to 31, wherein the active agent is an antibody or a peptide, and step (a) is performed before step (b).

33. 32. The process of any one of claims 29 to 31, wherein the active agent is a small molecule and step (a) occurs after step (b).

34. 34. The process of any one of claims 29 to 33, wherein each of the first linear polymer linker and the second linear polymer linker is added in an amount suitable to cover 5% to 60% of the surface of the inorganic nanoparticle.

35. A pharmaceutical composition comprising the nanodelivery system of any one of claims 1 to 28 and a pharmaceutically acceptable carrier.

36. 36. The pharmaceutical composition of claim 35, formulated for at least one of intravenous (IV), intranasal (IN), and intrathecal (IT) administration.

37. 37. A pharmaceutical composition according to any one of claims 35 or 36 for use in the prevention, treatment and / or monitoring of a brain-related disease or disorder in a subject in need thereof.

38. 37. A method for preventing, treating, and / or monitoring a brain-related disease or disorder in a subject in need thereof, the method comprising administering to the subject a pharmaceutical composition according to claim 35 or claim 36.

39. 39. The method of claim 38, further comprising imaging the brain of the subject, thereby assessing accumulation of the nanodelivery system in the brain of the subject.

40. 40. The method of claim 39, wherein the imaging is performed using an imaging system selected from the group consisting of computed tomography (CT), X-ray imaging, magnetic resonance imaging (MRI), positron emission tomography (PET), single photon emission computed tomography (SPECT), ultrasound (US), and any combination thereof.

Images